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Abstract 
 
The study of late-stage human African trypanosomiasis (HAT) within mouse 
models is lengthy and complex, with the removal of brain tissue being required to 
monitor parasitic burden. This results in the inability to track real-time infections 
within the central nervous system (CNS).  
 
With nearly 70 million people at risk of HAT infection in Africa every year, 
research into new drug therapies which are capable of crossing the blood brain 
barrier and efficacious towards the parasite are imperative. However, progress has 
been slow and difficult, partly due to the limitations with the current drug relapse 
mouse model for African trypanosomiasis (T. b. brucei GVR35), which requires a 
follow-up time of 180-days. 
 
In this study, we report the generation of highly bioluminescent parasites and their 
use in an in vivo imaging model of late-stage African trypanosomiasis. Bloodstream 
forms of the chronic model strain GVR35 were transfected with a “red-shifted” 
luciferase, which produced detectable signal in CNS at 21-days p.i mimicking that 
of the wild type line. This model enabled the tracking of a single animal through 
the entire chronic infection, with the detection of parasites occurring earlier than 
blood film microscopy.  
 
The model was further employed to assess the effects of known anti-trypanosomal 
drugs on bioluminescence, and to demonstrate how the reduction in 
bioluminescent signal combined with qPCR can determine a dose-dependent effect 
after treatment. 
 
The non-invasive in vivo imaging model will reduce the time and numbers of mice 
required to assess preclinical efficacy of new anti-trypanosomal drugs. 
This study shows the development and optimisation of a new, efficient method to 
evaluate novel anti-trypanosomal drugs in vivo with the added advantage of 
reducing the current drug relapse model from 180-days to 90-days.  
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CHAPTER 1: Introduction 
1.1 Challenges of central nervous infections 
 
One of the hardest challenges facing drug development projects in neglected 
diseases, is the treatment of neurological parasitic infections. The complex balance 
of anti-parasitic activity and low toxicity is problematic. The therapeutic needs to 
be able to cross into the brain at concentrations that are effective to kill the 
pathogen for a sustained period of time to reduce complex treatment regimens 
(Nau et al., 2010).  
 
New treatments are always a priority when dealing with disease and infections, 
but the ability to diagnose and understand the pathogen and its burden is essential 
in elimination and eradication programmes. Burden is an inherently difficult 
aspect to assess in neglected tropical diseases. The remote nature of most endemic 
areas and the limited access to medical facilities, prevents the recording of the 
disease and correct diagnosis (Jannin and Gabrielli, 2013). Neurological infections 
are often mis-diagnosed based on symptoms rather than the infective pathogen. 
This has resulted in epilepsy being a widely recorded condition in endemic areas 
as seizures are a common manifestation of most central nervous system (CNS) 
infections. The diagnosis of epilepsy has resulted in many diseases remaining 
untreated (Jannin and Gabrielli, 2013). 
The pathogenic invasion of the CNS during an infection is often rare but can cause 
severe complications for the host if left untreated (Finsterer and Auer, 2013). For 
some pathogens, the CNS may not always be the intended destination, for others 
CNS invasion acts as an important survival step of host evasion (Masocha and 
Kristensson, 2012).  
 
In order for a pathogen to successfully reach the CNS, they need to breach, cross or 
evade physical and immunological barriers. The two most well-known physical 
barriers within the CNS are the blood-cerebrospinal fluid (blood-CSF) barrier and 
the blood-brain barrier (BBB), both of which are responsible for keeping 
potentially harmful substances circulating in the blood, away from the brain and 
spinal cord.  
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1.1.1 Blood-cerebrospinal fluid (Blood-CSF) barrier and CSF-brain interface 
 
The CSF is a clear liquid produced by the choroid plexus that is responsible for 
providing an optimum environment for neurological mechanisms (Finsterer and 
Auer, 2013). CSF circulates around the brain and spinal cord within the ventricular 
system, and can be used as a marker in determining brain dysfunction through the 
analysis of lumbar puncture samples. To ensure that the internal environment 
remains regulated and protected against unwanted molecules, a blood-CSF barrier 
exists within the choroid plexus (Fig 1.1). 
Figure 1.1. Blood-CSF barrier. The endothelial cells have large gaps between them allowing easy 
access to the basement membrane. Further entry into the CSF is halted by tight junctions being 
present between the choroid cells (Source: http://fblt.cz/en). 
 
The barrier consists of three parts; choroidal epithelial cells, basement membrane 
and endothelium of the pia mater capillaries. 
As a barrier it is relatively permeable, with the movement of plasma proteins being 
possible through active transport or pinocytosis. Permeability of the barrier is due 
to gaps (fenestrations) in the endothelium of pia mater capillaries. Plasma proteins 
and macromolecules are able to pass through the endothelium, but due to the 
choroid epithelial cells being connected by tight junctions they become trapped 
within the basement membrane.  It is thought that the tight junctions provide the 
selectivity of the barrier, limiting the movement of molecules through and into the 
CSF as no fenestrations are present between the choroid cells (Kristensson et al., 
2013). 
 
  
17 
Structures are present that separate the CSF and the brain tissue, whilst these are 
not barriers they do consist of similar cells seen in both the blood brain barrier 
(BBB) and blood-CSF. The structures; pia-covered surface of spinal cord and brain, 
perivascular extensions of the subarachnoid space and the ependymal surface. The 
notable difference between these structures and the barriers, is the lack of tight 
junctions, which may explain why molecules are able to pass through from the CSF 
into the central nervous system with little resistance (Masocha and Kristensson, 
2012).  
1.12 Blood-brain barrier (BBB) 
 
The blood-brain barrier (BBB) isolates and protects the CNS from the blood to 
provide a stable environment free from microbes and large or hydrophilic 
molecules. The structure of the  barrier is a complex, highly specific, semi-
permeable membrane that restricts the movement of molecules from blood vessels 
to the brain (Kristensson et al., 2013).  
BBB occurs along the capillaries in the CNS and like the blood-CSF barrier, consists 
of three parts; a layer of endothelial cells, basement membrane and astrocytic feet 
(Fig. 1.2).  
The first point of contact of the blood is a wall of tightly packed endothelial cells 
with no fenestrations (normally present in other endothelium, as in the blood-
CSF). The endothelial cells are interconnected by tight junctions that cause the 
selectivity of the barrier and prevent the passage of molecules through. The tight 
junctions themselves are a collection of transmembrane proteins such as occludin, 
claudins and junctional adhesion molecules (JAM), which are fixed to the 
endothelial cells by protein complexes (Kristensson et al., 2013).    
The basement membrane (also known as the basal membrane) is a matrix of basal 
lamina of astrocytes and basal lamina of endothelial cells. It separates the 
endothelial cells from the astrocytes and acts as an additional barrier in the 
protection of the CNS. 
The astrocytes are glial cells found on the neural basement membrane, adhering to 
the outer surface of the capillary wall via astrocytic “feet” (Fig. 1.2). 
The cells do not have a substantial role in the maintenance of the BBB, but are 
involved in the regulation of blood flow into the brain (Masocha and Kristensson, 
2012). 
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Figure 1.2. Structure of the blood-brain barrier BBB. Unlike the blood-CSF barrier, the tight 
junctions appear in between the endothelium with no fenestrations being present. The astrocytic 
feet anchor the astrocytes to the basement membrane (adapted from http://fblt.cz/en).  
 
The permeability of the membrane is related to the size of the molecule. Larger 
molecules move slowly across the barrier (glucose etc.), whereas water and gas 
are able to pass through readily. Plasma proteins and compounds with large 
molecular weight (> 60, 000 kDa) are unable to cross (Masocha and Kristensson, 
2012). The overall structure of the BBB results in a hydrophobic nature, allowing 
only lipophilic substances to penetrate unless appropriate transport channels are 
expressed by the endothelial and astrocytes (Fig. 1.3) 
 
 Figure. 1.3. Passage of molecules through the BBB. Small and lipophilic molecules are able to 
move through the BBB freely by passive diffusion. Facilitated diffusion and active transporters 
allow glucose, GLU-1 and amino acids passage into the brain. Specific larger and macromolecules 
can be transferred using transcytosis and pinocytosis. (Source: http://fblt.cz/en 2013). 
 
As described above, the prominent role of the BBB is to maintain an internal 
environment within the brain, free from unwanted molecules and pathogens. But 
astrocyte feet 
Pincocytosis 
macromolecules 
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in the event of a CNS infection, the BBB also acts as a protective layer against the 
entry of antibodies and drugs. The CNS was once thought as being an “immune-
privileged” site, where the presence of immune cells were unable to enter resulting 
in a lack of inflammatory response. However, over the past twenty years this 
theory has been challenged as CNS macrophages (microglia) have been detected 
within the system, and there is evidence that an interaction of peripheral immune 
cells with the CNS endothelium occurs (Kristensson et al., 2013). 
Not all areas of the brain have a BBB. The circumventricular organs (CVOs) have 
large vasculature providing an alternative route for hormones and other molecules  
to enter the CNS (Kristensson et al., 2013). 
1.2 CNS parasitic infections 
 
As mentioned earlier, not all pathogens have the CNS as their target for infection. 
Parasites that infect the CNS fall into two categories. (i) Single-celled protozoa such 
as, malaria, toxoplasmosis and Human African trypanosomiasis and (ii), multi-
cellular metazoan such as, flatworms (including trematoda and crestoda) and 
roundworms (Pittella, 2013). The diagnosis of CNS infections is extremely difficult 
as most parasites either cause a self-limiting infection or are asymptomatic 
(Finsterer and Auer, 2013).   Here, we provide a brief overview of single-celled 
protozoan infections, their interaction and in some cases invasion of the CNS. 
1.2.1  Cerebral malaria 
 
Cerebral malaria (CM) is the neurological complication of severe Plasmodium 
falciparum (P. falciparum) malaria infection (Pittella, 2013).  P. falciparum is a 
intracellular apicomplexan parasite that is transmitted by the Anopheleine 
mosquito during a blood meal and causes one million deaths each year (Postels 
and Birbeck, 2013). The complication of severe malaria and consequently CM 
occurs in patients with little or no background immunity to the parasite, and 
causes nearly half of the total deaths from malaria each year (Newton et al., 2000). 
 
P. falciparum undergoes a complex multi-staged life-cycle, that involves a 
vertebrate host (human) and an invertebrate host (mosquito), and it is the human 
host that we will focus on. There are three distinct phases within the human host. 
(1) The exo-erthrocytic schizogony occurs after the injection of plasmodial 
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sporozoites into the host by the mosquito. The sporozoites rapidly migrate to the 
liver and undergo asexual reproduction in infected hepatocytes to produce hepatic 
schizonts. (2) The erythrocytic schizogony stage occurs after the matured hepatic 
schizonts rupture, releasing merozoites into the bloodstream. At this stage the 
merozoites rapidly invade the red blood cells (RBCs) and undergoes maturation 
from young ring to schizont, containing 16-32 merozoites. Not all infected red 
blood cells (iRBCs) become schizonts, a proportion of rings commit to differentiate 
from the asexual to sexual (3) stage to become macro or microgametocytes which 
are taken up by mosquitos during a blood meal (Madigan, 2006). 
 
Clinical presentation of CM include; the asexual forms of the P. falciparum being 
present in the peripheral blood films and patients being in a potentially reversible 
unarousable coma (with no other possible causes). The coma is either spontaneous 
or it can develop one hour after a seizure (Idro et al., 2010).  
  
As with most CNS infections the exact cause of CM is largely unknown, but the 
invasion of P. falciparum  parasite into the CNS is not responsible for the 
neurological effects (Medana and Turner, 2006). Post-mortem samples of CM 
patients and work carried out with the rodent model P. berghei ANKA, has found 
that the sequestration of iRBCs to the endothelium in the cerebral vessels is 
necessary for the development of CM, but the initiation and maintenance pf coma 
requires other factors (Adams et al., 2002). The adhesion of the iRBCs to the 
endothelium requires a number of endothelial receptors including; intercellular 
adhesion molecule (ICAM)-1 and the scavenger receptor CD36. The adherence is 
mediated by the parasite antigen PfEMP-1 (Plasmodium falciparum erythrocyte 
membrane protein-1) (Idro et al., 2010). The receptors responsible for the 
sequestration are also involved in recruiting leukocytes during an inflammatory 
response.  
The cytoadherance of the iRBCs to the endothelial cells and the host immune 
response, causes a change in the BBB permeability which in turn leads to neural 
injury. The ‘leaky’ BBB is confirmed in patients with CM as an increase in albumin 
is found in the CSF, whereas normally the molecule is too large to pass through the 
barrier (Adams et al., 2002).  
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Upon treatment, CM coma can be reversed and many patients do not suffer any 
lasting neurological effects (Finsterer and Auer, 2013). But there have been cases 
where survivors have a sustained brain injury, manifesting as long-term neuro-
cognitive impairments. Current treatment therapies involve the intramuscular or 
intravenous injection of artesunate followed by a complete course of artemisinin 
combinational therapy (ACT). In children that may have signs of neurological 
impairment, cognitive rehabilitation is recommended, such as; behavioural and 
speech therapy as well as hearing aids, but unfortunately strict guidelines on 
assessing impairment have     not been established (Idro et al., 2010).  
1.2.2  Toxoplasmosis 
 
Toxoplasma gondii  (T. gondii) is an apicomplexan obligate intracellular parasite, 
which has the ability to infect and replicate in any nucleated mammalian or avian 
cell (Kamerkar and Davis, 2012). Toxoplasmosis effects a third of the world 
population and is one of the most common human zoonotic infection, with many 
patients being asymptomatic (Saadatnia and Golkar, 2012). CNS complications 
arise in immunocompromised hosts, where a reactivation of the latent infection 
occurs and can lead to the patient developing serious symptomatic manifestations 
(Saadatnia and Golkar, 2012).  
The zoonotic parasite exists as three forms; (1) the oocyst contains sporozoites 
and is produced during the sexual stage within the small intestine of felines. This is 
the infectious stage and can infect humans via cat excrement contaminated water, 
soil or vegetables. After ingestion, the oocysts rupture in the intestine and the 
sporozoites are able to infect the surrounding cells of the lumen.  (2) the tissue cyst 
is the more common form ingested by humans and is normally present in 
undercooked meat, like the oocysts, the tissue cysts also rupture when in the 
intestine. The rupturing of the tissue cyst produces bradyzoites that then proceeds 
to infect surrounding cells. (3) the final form is the tachyzoite, which is rapidly-
dividing with the ability to infect any nucleated cells. They are then able to 
disseminate to different tissues and produce a reactivation of a latent infection. 
The infection of sporozoites and bradyzoites into the intestinal cells, also results in 
differentiation to the proliferative tachyzoites which circulate in the blood and 
lymphatic system (Saadatnia and Golkar, 2012).  
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In addition to oral transmission, T. gondii is able to cross the placenta and infect 
the foetus in pregnant women with latent infections. The manifestations of the 
foetal infections can be severe and devastating, with symptoms including 
hydrocephaly, mental retardation, seizures, inflammation of the eyes and 
miscarriage or still-birth. The severity of the infection is dependent upon the point 
at which the mother is infected. Prior to pregnancy the foetus is protected due to 
the mothers antibodies, but later in pregnancy the symptoms become more severe 
(Saadatnia and Golkar, 2012).  
 
Toxoplasmosis in healthy individuals is usually controlled by the immune system. 
When the illness does manifest, it usually causes flu-like symptoms that may last 
for weeks or months before becoming dormant, it is then only reactivated during 
immunosuppression (Pittella, 2013). It is the major opportunistic infection in 
immunosuppressed patients (e.g. AIDS and organ transplant patients), with the 
reactivation of an infection giving rise to the symptoms of fever, confusion, 
headaches, seizures, nausea, poor coordination and the potentially fatal 
toxoplasmic encephalitis (TE) (Finsterer and Auer, 2013). 
 
The exact movement of T. gondii into the CNS is poorly understood and the 
parasite is able to move both intra and extracellularly (though predominantly it 
remains as an intracellular parasite) (Masocha and Kristensson, 2012). Research 
carried out by Lachenmaier et al found evidence to support the ‘Trojan horse’ 
theory. The infection of nerve cells, astrocytes and microglia in combination with a 
T-cell-mediated response, allows the parasites to enter the brain via 
transendothelial migration of the BBB (Fig. 1.4) (Lachenmaier et al., 2011).  
In immunosuppressed patients it has also been found that T. gondii can localise in 
the choroid plexus at the blood-CSF barrier which could be a potential point of 
entry into the CNS (Masocha and Kristensson, 2012). 
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Figure 1.4. Endothelial transmigration. Various adhesion molecules and their receptors on the 
endothelial cells modulate the entry of the infected leukocytes through the BBB. The tachyzoites 
infected cells induce an upregulation of activated cellular adhesion molecules on the inflamed 
endothelial cells, resulting in a leaky BBB. (Weiss et al., 2009) 
 
Educating individuals on how to avoid personal exposure to toxoplasmosis is 
currently the best method of prevention as no vaccine is currently available for 
humans, although not out of reach as life-long protection would occur (Saadatnia 
and Golkar, 2012). Early diagnosis in immunocompromised individuals can help in 
the treatment to prevent the onset of TE, and currently highly active anti-retroviral 
therapy (HAART) has effectively reduced the number of AIDS patients presenting 
with TE (Saadatnia and Golkar, 2012). Healthy symptomatic patients infected with 
toxoplasmosis can undergo an effective combination treatment regime of 
pyrimethamine, sulfadiazine and folinic acid, though the treatment is limiting for 
established TE infections (Finsterer and Auer, 2013). 
1.3. Human African trypanosomiasis 
 
Human African trypanosomiasis (HAT) is a multi-stage disease that manifests in 
two stages of an early and late stage, and it is the latter that involves the invasion 
of parasites into the CNS (Pentreath, 2004), and the focus of this study. 
 
HAT causes fewer than 8000 cases (as reported in 2013) a year with almost 70 
million people at risk within the African continent (WHO, 2013). Prevalence has 
greatly fluctuated over the last 100 years due to medical intervention and socio-
economic unrest.  Despite the high risk of infection, HAT is still classed as a 
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Neglected Tropical Disease (NTD) by the World Health Organisation (WHO) with 
very little advance in drug development over the past 50 years (Simarro, 2011). 
 
African trypanosomiasis is caused by an extracellular, unicellular kinetoplastid 
protozoan parasite Trypanosoma brucei (T. b) and transmitted by an infected 
tsetse fly (Glossina sp.) during a blood meal (Stevens, 2004).  
There are three subspecies of Trypanosoma brucei; T. b. brucei, T. b. gambiense and 
T. b rhodesiense (the latter two being responsible for the human infection) (Brun et 
al., 2010). 
 
T. b. gambiense is responsible for approximately 95% of all reported cases of HAT 
every year within central and western Africa and produces a chronic infection that 
may take anything from three months to two years to manifest (Kaiser et al., 
2011).  T. b. rhodesiense is a zoonotic parasite, with the primary reservoir being 
within game and livestock in eastern and southern Africa and causes an acute 
infection, with symptomatic manifestations occurring in a matter of weeks 
(Steverding, 2008). The third subspecies; T. b. brucei, found in cattle, causes the 
disease known as nagana and is non-infectious to humans. However, it can be used 
as a surrogate parasite in the study of trypanosomiasis (Brun et al., 2010). 
1.3.1 Parasite, lifecycle and pathogenesis 
 
Despite the differences in host infectivity and infection pathogenesis, the parasite 
and lifecycle of the three subspecies are identical (Fig 1.5).  
Figure 1.5 The trypanosome (Source: http://armymedical.tpub.com). (F) Flagellum is attached 
via the parabasal body at the posterior end of the trypanosome near the kinetoplast (K), and runs 
the entire length of the parasite. (K) contains mitochondrial DNA and is essential in reproduction 
and metabolism. (N) Nucleus contains DNA arranged in the form of genes and chromosomes. Its 
S  SURFACE 
COAT 
S 
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position varies depending on which form the trypanosome is in. (S) Surface coat is a dense 
structure that encases the entire cell body and flagellum (Nolan, 2004). 
 
Trypanosomes are pleiomorphic and exhibit three different morphological forms 
within the mammalian host, consisting of slender, intermediate and stumpy forms 
(Fig.1.6 and Table 1). 
Figure 1.6 Pleiomorphic stages of T. brucei ( Source: http://www.fao.org) 
 
During the early stages of trypanosomiasis, the slender forms are rapidly dividing 
and cause the haemolymphatic parasitaemia to increase logarithmically. Once cell-
density reaches a threshold, activation of density-sensing factors occurs and 
results in halting parasite division. At this point the slender forms morphologically 
differentiate into the non-replicating stumpy form (Nolan, 2004). The intermediate 
stage is often seen in in vivo models and appears neither slender nor stumpy.  
Recent studies have shown that trypanosomes isolated from the brains of mice 
infected with T. b. brucei AnTaT 1.1, have a very long slender morphology 
(extensively thinner and longer than in Fig. 1.6) and are highly motile moving in 
straight lines at high speed, therefore distinctly different from the blood slender 
forms (Mogk et al., 2014). 
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Table 1 Morphological differences between different life-cycle stage of trypanosomes. 
 
The extracellular slender forms found in the blood, are under constant challenge 
by the host immune system. The trypanosomes are able to evade the host immune 
attack by expressing approximately 1 x 107 variant surface glycoprotein (VSG) on 
their surface coat, which protects the parasite against lymphocytes and 
complement. The trypanosome contains several hundred VSG genes but only one 
VSG protein is expressed on the surface at a time in a process known as antigenic 
variation. (Barry, 2001). The process of antigenic variation is clonal and rapid, with 
each individual trypanosome undergoing spontaneous antigenic switching. This 
allows the parasite to evade the host immune response, as the formation of VSG-
specific antibodies will only clear part of the clonal population in the blood, as 
parasites that have already switched VSG are protected and will proliferate. (Barry, 
2004). Once the slender forms have differentiated into stumpy parasites they are 
no longer able to undergo antigenic variation and are therefore susceptible to 
immune response (Mogk et al., 2014). 
Understanding how antigenic variation occurs and a way to disrupt it can provide 
a potential drug target, as trypanosomes would then become vulnerable to an 
attack by the host immune system. 
 
T. brucei undergoes a complex multi-stage life-cycle involving a mammalian host 
and an invertebrate host (the tsetse fly) (Fig. 1.7). Within the human host the 
infection has three distinct phases; chancre formation, early (first) stage and late 
(second) stage HAT. 
 
Stage Length Position of Nucleus Flagellum 
Slender 23-30µm Central 
Free, spirals around 
parasite body 
Intermediate 23-25µm 
Off-centre, nearer 
posterior end 
Free, but slightly 
shorter than in the 
slender form 
Stumpy 17-22µm Nearer kinetoplast No 
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The trypanosomal chancre is a localised inflammatory response to the tsetse fly 
bite and initial injection of parasites. It typically appears approximately 48 hours 
after the fly has taken a blood meal and is the first sign of an infection. Patient 
reaction to the chancre typically differs; some find it disappears within a couple of 
days, whereas others find it very painful, persisting for up to three weeks 
(Sternberg and Maclean, 2010). The early stage  of infection occurs some weeks 
later as the parasite invades the haemolymphatic system (Pentreath, 2004). It is at 
this point that the differences between T. b. gambiense and T. b. rhodesiense 
infections are evident. In the acute infection of T. b. rhodesiense, symptoms can 
occur immediately, as the infection progresses at a much faster rate. With a T. b. 
gambiense infection a patient may not see symptoms for several years. 
The common symptoms present during the early stages (haemolymphatic stage) of 
HAT include an irregular fever pattern, joint pain, itching, enlargement of the 
spleen and in gambiense infections, a characteristic enlargement of the lymph 
nodes known as Winterbottom’s sign (enlargement of the posterior cervical group 
of lymph nodes) (Bscher, 2004). 
 
The late stage, also known as the meningoencephalitis stage is characterised by the 
parasites invading the central nervous system (CNS) through the blood-brain 
barrier (BBB).  How the parasites pass through the BBB remains under 
investigation and there are many theories regarding the mechanism of action. 
These theories include the involvement of immune cells and the use of 
intracellular junctions (Brun et al., 2010). The symptoms for the late stage are 
neurological and include confusion, personality changes, tremors and psychiatric 
symptoms. The primary symptom of the late stage is the disruption in sleep 
patterns, which is due to the infection causing a deregulation in the circadian 
rhythm. The differences between the late stages of the chronic (gambiense) and 
acute (rhodesiense) infection are more obvious, but in both cases, if left untreated 
the second stage will progress to coma leading to eventual death (Pentreath, 2004, 
Brun et al., 2010). 
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Figure 1.7. The life-cycle of Human African trypanosomiasis (CDC, 2009) 
1.3.2  CNS invasion by trypanosomes 
 
The penetration of trypanosomes into the CNS is still under investigation but they 
do exhibit some similarities with that of toxoplasmosis in its CNS penetration. 
Unlike P. falciparum, Trypanosoma and Toxoplasma do not actively damage the 
BBB to invade the CNS, and it is theorised that both use the presence of leukocytes 
and an immune response to gain entry (Finsterer and Auer, 2013). 
During early stages of infection, trypanosomes have been found to concentrate 
around the circumventricular organs and choroid plexus and are believed to cross 
into the choroid plexus and CVOs due to the lack of BBB. But despite being at the 
CSF-Brain interface, the trypanosomes do not cross the ependymal cell layer to the 
brain parenchyma (Kristensson et al., 2013). 
 
The introduction of trypanosomes within the choroid plexus and CVOs causes 
inflammatory changes in the brain parenchyma as well as an upregulation of 
adhesions molecules, and other immune cells (e.g., chemokine, cytokines etc.). This 
is evident by the increased number of white blood cells (WBCs) that are found in 
the CSF, which is used as a diagnostic tool. This influx of leukocytes is believed to 
be the ‘blanket of cover’ the trypanosomes require in order to access the brain, as 
it is theorised that the parasite enters the brain through important and short-lived 
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openings in the BBB caused by the entrance of T-cells (Masocha and Kristensson, 
2012).  
 
Masocha et al established that the migration of trypanosomes into the brain 
requires lymphocytes to be present, by using a rodent model of African 
trypanosomiasis which lacked B and T cells (RAG-1 mice). The model failed to 
establish a CNS infection, suggesting that trypanosomes penetrate the BBB using 
mechanisms similar to leukocytes or, that leukocytes alter the integrity of the 
basement membranes (Masocha et al., 2004). The study also confirmed that pro-
inflammatory cytokines played an important role in the parasite invasion as IFN-γ 
secreted by T and natural killer cells (NK) is predominantly responsible for the 
induction of macrophage trypanotoxic activities (Burgos et al., 2003). However, in 
IFN-γ  or IL-12 (major inducer of IFN-γ) deficient mice, a reduction in trypanosome 
infiltration into the brain parenchyma is seen, although an increase in systemic 
parasitaemia occured (Masocha et al., 2004).  
 
The detection of trypanosomes in the brain is inherently difficult and time-
consuming due to low parasitaemia. Neuropathological changes associated with 
African trypanosomiasis have been studied from histopathology samples obtained 
from animal models (due to a lack of post-mortem reports from human patients) 
and indicate that neuropathogenesis is predominantly due to an inflammatory 
response presenting as meningitis, encephalitis and perivascular cuffing (Bscher, 
2004). The occurrence of perivascular cuffing (accumulation of lymphocytes) in 
areas of vascularisation such as the thalamus, hypothalamus and choroid plexus, is 
common and indicative of CNS involvement in HAT but have not been proven to be 
responsible in the clinical features of late stage HAT (Burri, 2004). 
1.3.3  HAT Drugs 
 
When a patient presents with HAT it is preferable to know the strain and stage 
(early or late) of the infection (though this is not always performed) before 
treatment is administered. This is due to the four registered anti-trypanosomal 
drugs being both strain and stage specific. 
  
30 
 
Early stage Late stage 
T. b. gambiense pentamidine 
• melarsoprol 
• eflornithine (DFMO) 
• DFMO & nifurtimox 
combination therapy (NECT) 
T. b. rhodesiense suramin • melarsoprol 
Table 1.2. Current therapies in the treatment of gambiense and rhodesiense HAT (WHO, 
2009) 
 
As the main focus of this study is on late stage HAT, the treatments for the early 
stages of gambiense and rhodesiense trypanosomiasis of pentamidine and suramin 
will be covered briefly.   
 
Suramin was developed in Germany and first used in the treatment of sleeping 
sickness in 1922. It is now produced by Bayer under the name Germanin® (Burri, 
2004). It was initially used for first stage treatment in both T. b. rhodesiense and T. 
b. gambiense and also in the clearance of Onchocerca spp. infections (Brun et al., 
2010). However, due to some patients developing a severe allergic reaction to the 
clearance of Onchocerca infections in T. b. gambiense endemic areas, suramin 
treatment is now only carried out in T. b. rhodesiense  cases (Burri, 2004). 
After suramin treatment for gambiense ceased, pentamidine was introduced in 
1941 under the commercial name of Pentacarinat (Dorlo and Kager, 2008). 
Despite having a high cure rate of 98% in gambiense infected patients, failures are 
extensive in rhodesiense sleeping sickness which may be due to poor uptake by 
the rhodesiense parasite (Burri, 2004). 
 
As the infection moves into the later stage of the disease and invades the CNS, 
different drugs are required that are able to cross the blood brain barrier. Table 
1.3 indicates the current therapies for late stage disease are; melarsoprol, 
eflornithine (as a 2nd line treatment to melarsoprol failures) and the combinational 
therapy NECT (nifurtimox and eflornithine).   
 
Melarsoprol (Arsobal®) was the most widely used drug in the treatment of late 
stage HAT in both gambiense and rhodesiense infections and has been used for HAT 
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since 1949. The wide use of the drug is in part due to its affordability and currently 
it is the only treatment available for rhodesiense infection (Barrett et al., 2007). 
Melarsoprol can produce a severe toxic side effect known as post-treatment 
reactive encephalopathic (PTRE) syndrome (table 1.3)(Stein et al., 2014). Chapter 
4 provides further details on melarsoprol. 
 
Eflornithine (DL-α-difluromethylornithine, DFMO) is one of the newer drugs to be 
introduced for the treatment of late-stage HAT. Originally designed for use in 
tumour chemotherapy, it was first trialed as an alternative to melarsoprol in 1981 
by Van Nieuwenhove et al, after Bacchi et al confirmed its anti-trypanosomal 
efficacy in vivo (Bacchi, 1980, Van Nieuwenhove, 1981b). It is currently produced 
by Sanofi under the brand name of Ornidyl®. As mentioned earlier, DFMO can be 
used as a 2nd line treatment in melarsoprol failures, and is known as the 
“resurrection drug” as comatosed patients recover shortly after administration. 
The use of DFMO in the treatment of rhodesiense infections is strongly discouraged 
due to the drugs poor efficacy to the parasite (Burri, 2004). The very short half-life 
(3 hours) of DFMO means that the treatment administration requires intravenous 
infusion of large doses (Stein et al., 2014). In the early use of DFMO, it was given as 
an oral treatment as a way to reduce the need of hospitalisation for patients in 
rural areas. However, pharmacokinetic studies found absorption and effectiveness 
were seriously hindered with this method of administration (Na-Bangchang, 
2004). Chapter 5 provides more information on DFMO and its mechanism of 
action. 
 
Nifurtimox was introduced in the 1960s for the treatment of American 
trypanosomiasis (Chagas disease). In the 1980s, it was found to be poorly effective 
in studies with African trypanosomiasis, but there was still interest in using 
nifurtimox in combination with DFMO to treat late stage infection (Priotto, 2006). 
NECT  (nifurtimox and eflornithine combinational therapy) was placed on the 
WHO Essential Medicines List in 2009 as an approved alternative treatment to 
melarsoprol and is currently the first-line treatment for late-stage HAT due to its 
less painful application than the individual monotherapies (Stein et al., 2014, 
Simarro, 2011). Chapter 5 provides further details on nifurtimox. 
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Currently there are two drugs in clinical trials for the treatment of HAT; 
fexinidazole and SCYX-7158 (DNDi, 2014).  
Fexinidazole is an oral nitroimidazole drug re-purposed by the Drugs for Neglected 
Diseases initiative (DNDi) and is currently in Phase-2 and 3 clinical trials, with the 
plan of drug registration by the end of 2016 (DNDi, 2014). Preliminary studies 
have shown that it is orally effective in curing both chronic and acute stages of the 
disease in mice (Kaiser et al., 2011) (further details on the drug can be found in 
chapter 6).  
 
SCYX-7158 is an orally-active benzoxaborole that has been shown to be effective in 
the cure of both early and late stage HAT in murine models at low doses 
(25mg/kg). The mechanism of action is understood to be the inhibition of serine 
proteases, which is common with boron-containing compounds. SCYX-7158 is 
currently in Phase-1 clinical trials and is one of the first candidate to enter clinical 
trials from the DNDi Lead Optimization Consortium, with drug registration 
planned for the end of 2018 (Nare et al., 2010, Wring et al., 2014). 
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1.3.4 Rodent Models of HAT 
 
The use of animal models in the study of any infectious disease, can not only 
provide useful information about the interactions of the pathogen with the host 
immune system. It can also be a helpful tool in drug discovery programmes to 
determine targets and are necessary for efficacy testing of the drug in an infected 
host. 
T. b. brucei, the parasite responsible for some forms of trypanosomiasis in cattle, is 
the most commonly used parasite line in both the laboratory and animal unit for 
the study of African trypanosomiasis. The strain T. b. brucei Lister 427 is a well-
defined monomorphic line, remaining solely as the blood-stream form (BSF) of the 
parasite.  
Lister 427 is often used in efficacy trials of drugs aimed at the blood-stage of the 
disease, as it can easily infect outbred mice and, due to its virulence, kills mice 
within 7-10 days making it a very quick high-throughput drug experiment. 
T. b. brucei GVR35 is a pleiomorphic strain that is commonly used to study CNS 
infection, as trypanosomes are able to cross the blood brain barrier, with a survival 
rate of approximately 40 days in mice. This model allows drug relapse to be 
detected in either the CNS or peripheral parasitaemia. Currently the GVR35 model 
requires 180-days of follow up to allow parasites to move into the periphery from 
the CNS, and therefore detectable via blood films (Jennings et al., 2002).  
GVR35 can also be easily cultured in vitro, but at a slower rate than Lister 427 and 
requires different culturing techniques due to the parasite having the ability to 
differentiate to the stumpy form.  
 
Models of T. b. rhodesiense are often used to assess drug efficacy against the early-
stage of the disease due to the acute nature of infection, and normally used as a 
secondary screen after successful data obtained from Lister 427. STIB 900, derived 
from STIB704 is a commonly used strain both in vitro and in vivo as it is drug 
sensitive and can be easily cultured. STIB900 can successfully infect inbred strains 
of mice, without the requirement of immunosuppression and mice are normally 
overwhelmed by parasitaemia and die at approximately day 6 post-infection 
(Kaiser et al., 2011). 
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Though a chronic infection model of  T. b. gambiense  in albino rodents (rats and 
mice) was first obtained in 1981 by Beckers et al (Beckers, 1981), use and 
reproduction of the model has been limited in recent years. The key problem with 
rodent models of T. b. gambiense is the low virulence in immunocompetent mice, 
with very low parasitaemia that can take many months to appear. The low 
parasitaemia can be problematic when studying drug efficacy, as numbers are too 
low to determine if an effective dose has been reached. Using immunosuppressed 
or severe combined immune-deficient (SCID) mice can help to obtain initial 
infections and to boost parasitaemias. The use of cyclophosphamide and 
irradiation to immunosuppress mice prior to infection helps to increase 
parasitaemia to >106/ml, enabling the harvest of parasites much easier. However, 
immunosuppression does not always produce uniform infections and low CNS 
infections (confirmed primarily by the presence of immune cells within the brain) 
usually occurs. There is also some discrepancy on how often mice should be 
treated with the immunosuppressant, not to mention the added problem of drug-
treating mice prior to a drug study, as drug to drug interaction may be an issue 
(Brun, 1999). Due to GVR35 being able to replicate a CNS infection within mice, it 
is commonly used as a surrogate in the drug evaluation and study of CNS infection 
in HAT. 
 
When carrying out studies in rodents it is important to understand the limitations 
of the models and be aware of the physical differences between rodents and 
humans. In CNS infection studies this is especially important as there is limited 
access to infected human brain tissue for comparison. Although the brain 
organisation of humans and mice are similar, anatomical and cellular differences 
are more apparent (Simeonova and Huillard, 2014). Anatomically the most striking 
difference between the human and mouse brain is the structure of the neocortex. 
Within the mouse brain, the neocortex is smooth and only covers the top of the 
brain, whereas the human neocortical surface covers the entire brain and has 
many folds (or sulci). Within the folds there are several subclasses of astrocytes, 
whose function is currently unknown (Simeonova and Huillard, 2014). On a 
cellular level, the astrocytes present in the human brain are larger, more complex 
and signal considerably faster than that of the mouse. This explains how humans 
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are able to process complex information faster than rodents (Oberheim et al., 
2009).  
These differences may result in alterations in CNS invasion and persistence within 
the rodent model compared to human infections but it is difficult to predict to 
what extent. Regardless of these issues, the use of predictive mouse models have 
provided information about the relationship between CNS and parasites that 
would of otherwise remained a mystery. 
1.4 Drug discovery and development 
 
Inefficiency and resistance of drugs are not the only factors preventing control and 
elimination of HAT. One of the major problems with the drugs currently used in 
HAT treatments are their availability and costs to the poorer rural towns in Africa. 
The complex and prolonged treatment regimens for the drugs, force the overall 
cost of treatment to levels that could never be afforded in the disease endemic 
areas (DEAs). A campaign led by the WHO is currently in place to ensure that 
much-needed drugs are available and supplied to the DEA. This has been achieved 
by the public-private partnership (PPP) of Bayer and Sanofi with the WHO to 
donate and distribute the anti-trypanosomal drugs. The campaign was first set up 
in 2001, initially for 5 years and was continually renewed based upon evidence 
that the number of patient cases have continued to decline since its inception 
(Simarro, 2011). 
 
Figure 1.8 Process involved in drug discovery. It can take an average of 12 years for a new drug 
to enter the pharmacy. Preclinical development (highlighted in red) is the area where discoveries 
made in this project will be most beneficial. 
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Whilst the access to free treatment has markedly improved the availability of 
drugs, the number of cases being reported, by no way detracts from the need to 
develop new chemotherapies, as resistance is slowly emerging in the small 
number of drugs available. But without the full understanding of the parasite and 
pathology of the disease, new drugs are difficult to discover and therefore a switch 
in research to understand both parasite and pathology becomes paramount in 
drug discovery, which can be achieved by using animal models to reproduce 
infections. 
1.4.1 Importance of pharmacokinetics and pharmacodynamics 
 
Within drug development, efficacy of a new compound to the pathogen is only part 
of the challenge. By understanding the pharmacology of a compound at early 
stages of development, a more effective approach to drug research and 
development can be achieved.  
 
Pharmacological studies look at two important factors; (i) the effect the host has 
on the drug (pharmacokinetics, PK) in terms of its absorption, distribution, 
metabolism and excretion (ADME), and (ii) the effect the drug has on the 
host/pathogen in terms of its drug action (pharmacodynamics, PD) (Drusano, 
2004).  
Establishing the PK-PD relationship of a new drug determines the interactions 
between the drug’s potency, its exposure in target tissue (in the case of late stage 
HAT, the brain) and also the length of time the tissue is exposed to the drug to 
ensure cure (Wring et al., 2014).  
Whereas previously the study of PK-PD usually occurred towards the end of pre-
clinical trials when potency of a drug is established, by using PK-PD predictive 
models at early stages of drug development we can determine if the plasma 
(central compartment) and target tissue (peripheral compartment) concentrations 
of the drug are at a relevant therapeutic level to render cure (Wring et al., 2014).  
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PK-PD predictive models determine optimised dosing regimens that enable the 
minimum inhibitory concentration (MIC) of the drugs to be maintained in tissue. 
This is carried out by assessing the total drug exposure over time (calculated by 
the area under the curve, AUC) and ensuring that levels are above the MIC (Fig. 
1.9). 
 
Figure 1.9. PK-PD relationship of drug concentrations against time. For a drug to kill a 
pathogen it needs to remain above the MIC in the target tissue for an extended period of time. The 
Cmax is the maximum concentration of drug after a single dose Source (Wring et al., 2014).  
 
The determination of the MIC is normally obtained from a static inhibition assay 
after a set period of time (frequently used trypanosome assays is 72 hours). The 
methodology to determine the AUC/MIC relationship has been the most commonly 
used and well established, but it fails to take into consideration protein binding, 
tissue distribution and kill-rate of the drug. By also assessing the Cmax/MIC it is 
possible to look at how the maximum concentrations obtained after a single dose 
can alter the efficiency and rate of pathogen death.  
 
Using a dynamic predictive model in combination with the AUC/MIC and/or 
Cmax/MIC models we can gain a greater understanding of the relationship between 
time and concentration of drug. This can also be achieved with in vitro time-kill 
assays where the rate of kill of a drug can be assessed to be either concentration or 
time dependent (Mueller et al., 2004). 
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The penetration of drugs entering the CNS is restricted due to the highly specific 
BBB, with many drugs being denied access or encountering a slow diffusion (water 
soluble drugs) through the tightly linked endothelium, whereas lipid soluble drugs 
are able to move rapidly into the brain through passive diffusion and would 
therefore provide rapid concentrations after dose (Wring et al., 2014). Assessing 
the plasma and brain concentrations of drugs in infected and uninfected mice can 
establish the proportion of dose that is able to pass through the BBB, and whether 
that differs in an infected host. As detailed earlier, some CNS infections can cause 
an increase in permeability in BBB, which will allow a larger proportion of drug to 
enter which is important to establish for dose ranging purposes. 
 
By confirming tissue distribution, dose-ranging properties through AUC/MIC, 
protein binding and time-kill in early stages of drug development, long lengthy in 
vivo efficacy studies can be avoided in potential failure compounds. Most PK-PD 
studies can be carried out in vitro or in uninfected mice, making them easily 
achievable in most laboratories. 
1.5  Bioluminescence Imaging  
 
The method of bioluminescence imaging (BLI) has become a powerful tool in 
monitoring real-time infections in a single animal.  
BLI is based on the emission of light in the visible-spectrum (Fig. 1.10) produced 
by a luciferase-catalysed reaction. The emitted photons are then detected by a 
charge coupled device (CCD) camera, which is able to convert the light photons to 
electrons (Sadikot and Blackwell, 2005).  
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Figure 1.10 The visible spectrum. The human eye is able to see electromagnetic radiation (light) 
from wavelengths 390-700 nm. (http://myweb.rollins.edu/jsiry/Biophysical.html) 
 
The naturally-occurring luciferase enzymes involved in the genetic manipulation 
of pathogens or (for some studies) mice, can be obtained from a number of 
different sources including; (1) bacteria Vibrio fischeri and Vibrio harveyi 
(bioluminescent marine bacteria). (2) the jellyfish Aequorea. (3) insects such as the 
North American firefly (Photinus pyralis) that produces the firefly luciferase FLuc 
and the click beetle (Pyrophorus plagiophthalamus) producing click beetle 
luciferase, CBR. (4) the sea pansy (Renilla reniformis) which produces the Renilla 
luciferase, RLuc (Sadikot and Blackwell, 2005).  The most widely used reporters 
are RLuc and FLuc. 
 
The benefit of using bioluminescent rather than fluorescent reporters, is that 
bioluminescence has a very high signal-to-noise ratio which allows the system to 
be very sensitive due to the lack of intrinsic bioluminescence. Unlike fluorescence, 
bioluminescence does not require excitation, which results in negligible 
background signal (Keyaerts et al., 2012). For the luciferase reporters to emit light, 
a luciferase-catalysed reaction is required, but the substrate needed depends on 
the reporter. RLuc requires the presence of the substrate coelentrazine and oxygen 
to produce light in the blue region of the spectrum at 480nm. For FLuc, the 
substrate D-luciferin in addition to oxygen and ATP is needed to produce light in 
the green area of spectrum at 562 nm (Taylor and Kelly, 2014). Both substrates are 
not produced by mammalian cells and therefore require them to be added (or 
injected) prior to imaging (Hutchens and Luker, 2007).  
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Bioluminescent transfected lines can be used in vitro and in vivo, providing a range 
of research opportunities. By using opaque tissue culture plates, 
spectrophotometers with the ability to detect bioluminescence can be used for fast, 
highly sensitive assays. However, with the advancements in technology over the 
last decade whole animal bioluminescence in vivo imaging has become affordable 
and groundbreaking for many inaccessible, difficult areas of research (Fig 1.11) 
(Sadikot and Blackwell, 2005). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.11 In vivo imaging system. The IVIS Lumina is a light-tight box (A) with a super-cooled 
CCD camera mounted above (B). The super-cooling and light-tight box reduces the background 
noise to negligible quantities allowing highly sensitive imaging to take place. The camera is 
controlled by a computer that carries out image acquisition and analysis (C). An inhalation 
anaesthesia unit (D) provide a slow pump of iso-flourane into the chamber allowing the animals to 
be safely imaged with minimal stress and fast recovery.  
 
Photographs of the animals are first taken and a bioluminescent image overlaid. 
The bioluminescent image is a heat-map scale, with areas of high bioluminescence 
signal (high photonic output) represented in the red area of the scale (Fig. 1.12). 
Without specialised software the images are purely qualitative, indicating areas of 
high luminescence emitting cells. The software is able to quantify the signal as the 
number of photons per second of exposure in a region of interest (ROI). 
 
 
 
 
 
 
 
A 
B 
C D 
  
42 
 
Figure 1.12 BLI analysis and heat map scale (A) the bioluminescence can be quantitated and 
therefore compared by analysing the same size of area animal on each acquired image. (B) The heat 
map scale indicating high photonic signal in red and low signal in blue. The scale ranges can be 
altered at analysis stage using imaging software. Depending on the ranges and strength of 
bioluminescent strains, two scales maybe needed during the course of an infection (showing low 
infection and high infection) or a logarithmic scale can be used. 
1.5.1  Limitations 
 
As with all technologies there are limitations to BLI but advances have been made 
to try and overcome some of the restrictions. 
The catalytic reaction requires all factors to be present, oxygen, substrate and (in 
the case of FLuc) ATP. If any of these are not present in large quantities or if the 
substrate is not uniformly distributed throughout the animal after administration, 
light emission may not be a true representation of bioluminescence activity (Badr 
and Tannous, 2011). For example, coelentrazine has shown poor distribution and 
difficulty in crossing cellular membranes which would provide a false 
representation of bioluminescent cells (Hutchens and Luker, 2007). D-luciferin 
however, has been shown to distribute throughout the mouse and is able to 
penetrate blood-tissue barriers. It can also be administered via a number of dosing 
route, but intraperitoneally (i.p.) is often chosen for ease of use, but does not affect 
the level of signal produced, reaching a plateau at 10 minutes post administration 
(Keyaerts et al., 2012).   
Highes
t 
Lowest 
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The transmission of light through tissue is wavelength dependent and is one of the 
biggest problems with BLI. Tissue absorption is at its highest when 
bioluminescence at the lower end of the spectrum is used. This is due to an 
increase in light scatter at the shorter wavelengths. In addition to this haemoglobin 
is a chromaphore that absorbs light in the 420 - 550nm part of the spectrum (blue-
green), resulting in poor signal intensity (Fig 1.13.) 
To avoid high levels of tissue absorption, reporters that emit light above 600nm 
are best to use. By genetically manipulating the reporters, a “red-shifted” FLuc has 
been produced known as PpyRE9, which emits light at a maximum of 617nm 
(Branchini et al., 2010).  
 
Figure 1.13. Tissue absorption in in vivo imaging. A reduction in tissue absorption is seen with 
bioluminescent reporters producing light above 600nm (Source: Adapted from (Deliolanis, 2008). 
1.5.2   Bioluminescence models of infectious disease 
 
Prior to the development of new technologies, the study of host-pathogen 
interactions and the progress of infections involved the euthanasia of vast 
numbers of experimental animals at multiple time points to determine pathogen 
burden. The conventional method provided many limitations, the spread of 
pathogens to tissues and organs could not be effectively monitored without 
invasive measures, the course of infection could not be traced within an individual 
animal for an entire experiment and the setting of multiple time points may miss 
certain infection events. 
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The development of BLI addressed these limitations and enabled researchers to 
gain a more rounded understanding of infection processes in different pathogens.  
The engineering of bioluminescent strains has been carried out in viruses, bacteria, 
yeast, and protozoa.  Here, we briefly detail the advancements in bioluminescence 
protozoa models over the last decade. 
 
Bioluminescence models have been developed for Toxoplasma gondii to study 
virulence between strains, infection susceptibility after immune manipulations 
(various toll-like receptor knock-out mice), as well as reactivation of parasites 
during a chronic infection (Hitziger et al., 2005, Saeij et al., 2005). The models all 
express FLuc, emitting light in the green part of the spectrum, which affect the 
depth of tissue imaging possible, nevertheless the models have shown that the 
manipulation of T. gondii is possible and that BLI can be used to further investigate 
the pathology (Hutchens and Luker, 2007). 
 
The parasite responsible for cutaneous Leishmaniasis, L. amazonensis, has been 
successfully manipulated to produce a firefly bioluminescent model of infection. 
The model has been predominantly used in cell culture for drug therapy 
evaluation, but it has also provided information on parasite burden in excised 
organs from mice (Lang et al., 2005). 
 
To gauge a better understanding of malaria, the rodent malaria strain Plasmodium 
berghei was engineered to express the firefly luciferase by Franke-Fayard et al. The 
strain was able to provide bioluminescence in all parasite life stages, they were 
able to locate iRBCs (infected with schizonts) sequestered in the microvasculature 
of the lung and also adipose tissues (Franke-Fayard et al., 2005). Due to the 
complete lifecycle being able to express the bioluminescence, closer investigations 
can be carried out to understand the parasites interactions at each stage and 
monitor pathogenesis in the host. 
 
Chagas disease (Trypanosoma cruzi) has been difficult to study in animal models 
due to the lengthy experimental times (often up to six months), the lack of 
circulating extracellular trypamastigotes and the sub patent parasitaemia means 
that parasite burden is difficult to determine. Hyland et al developed a transfected 
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strain of T. cruzi that utilised the FLuc reporter expressing light in the blue-green 
spectrum. Whilst this model was able to demonstrate the dissemination of the T. 
cruzi infection throughout the mouse model, the level of bioluminescence was very 
low, which would cause potential issues when dealing with drug therapy analysis 
and imaging parasites deep within tissues (Hyland et al., 2008).  
To overcome the restrictions with this model, Lewis et al developed a new 
bioluminescent strain of T. cruzi using a red-shifted FLuc. This model provided a 
greater sensitivity and tissue penetration due to the longer wavelength of 617nm 
(Lewis et al., 2014a). The greater sensitivity has also enabled the model to be used 
as a drug evaluation model for the chronic infection as relapse can be detected 
(Lewis et al., 2014b).  
 
 Other Trypanosoma sp.  that has benefited from the development of BLI are those 
responsible for African trypanosomiasis. Claes et al were the first to develop a T. b. 
brucei bioluminescence imaging model expressing Renilla luciferase (emits light at 
490nm, purple-blue), in both a monomorphic and pleiomorphic strain (Claes et al., 
2009). Limitations with the model included the use of coelentrazine (as mentioned 
earlier) having a poor distribution around the body and is chemiluminescent 
resulting in high background bioluminescence. The Renilla produces light within 
the blue part of the spectrum which is largely absorbed by the tissues within the 
mice, making deep tissue imaging difficult (Taylor and Kelly, 2014).  
An advancement on the model was made by the University of Glasgow with a FLuc 
transfected line T. b. brucei GVR35 LUC2 emitting light in the green spectrum at 
approximately 500nm. By using the D-luciferin substrate a uniform distribution 
occurred, reducing the problems with luciferase-substrate reaction. In addition to 
the substrate issues, the sensitivity was increased as a longer wavelength than the 
Renilla was emitted and the model was successful in determining drug relapse 
(Myburgh et al., 2013). However, based on figure 1.12 the level of tissue 
absorption is still an issue at these wavelengths, resulting in the possibility of 
residual parasite being present but not detectable using the current BLI model. 
 
The development of an African trypanosomiasis bioluminescence imaging model 
utilising red-shifted proteins would enable a model to be produced that could 
detect drug relapse earlier. This would result in the length of experiment being 
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reduced, as the signal would be detected before peripheral parasitaemia is 
measurable. Ultimately this would enable a more efficient method of analysing 
drug efficacy. 
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CHAPTER 2: Materials and methods 
2.1  Parasite culture 
 
T. b. brucei Lister 427, isolated from cattle in Tanganyika (now Tanzania) in 1956 
was transferred to the Lister institute in London where it underwent serial syringe 
passage, was provided by Dr. Martin Taylor, LSHTM. T. b. brucei GVR35 WT/Cl.1, 
isolated in 1966 from a wildebeest in the Serengeti (Tanzania), was provided by 
Dr. Jean Rodgers, University of Glasgow.  
 
Frozen monomorphic strains (WT and transfected 427 lines) were fast thawed to 
room temperature (RT) and added to 9ml of modified HMI-9 media in a filter-top 
culture flask. Modified HMI-9 media (Hirumi and Hirumi, 1994) in powdered form 
(Invitrogen, UK) was re-suspended in dH2O supplemented with 10% v/v heat-
inactivated foetal calf serum, hi-FCS (Gibco, Life Technologies, UK) and 0.3% w/v 
sodium bicarbonate (Sigma Aldrich, UK). Parasites were monitored via 
haemocytometer counts 24 hours later and the HMI-9 media changed. Parasites 
were counted and passaged every 2-3 days. 
 
The pleiomorphic strains (WT and GVR35 transfected lines) were thawed as above 
and cultured in modified HMI-9 with the addition of sterile 0.01% w/v methyl 
cellulose (Sigma, UK). Due to the pleomorphic nature and slower growth of GVR35 
a lower parasitaemia needed to be maintained, passaging every 2-3 days at approx. 
2 x 104 trypanosomes/ml, to ensure the culture did not differentiate into the 
stumpy (non-replicating) form.  
2.2  Cryopreservation of trypanosomes 
 
Parasite morphology (in the replicating stage, slender) was examined by 
microscopy and parasitaemia was determined. The cells were mixed with a 
freezing buffer to protect the parasites. The total stabilate produced contained 8% 
glycerol (Sigma, UK), 20% hi-FCS and 72% of media (or blood) containing 
parasites. Parasites were aliquoted and slowly frozen at -80°C using a Mr. Frosty™ 
Freezing container (Nalgene, UK), before being transferred to liquid N2. 
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2.3  Construct development and transfection 
 
The pTb-AMLuc construct (McLatchie et al., 2013) containing the red-shifted 
firefly luciferase gene PpyRE9H (Branchini et al., 2010) was designed to integrate 
into the ribosomal RNA locus to provide strong RNA polymerase 1 – mediated 
transcription, resulting in high levels of expression (for further details see 
McLatchie et al., 2013). The construct was transfected into T. b. brucei 427 and 
GVR35 strains using the protocol described by Burkard et al 2007(Burkard et al., 
2007) by A. McLatchie. Parasites were selected with puromycin (1 µg/ml). The 
transfections produced the following strains. 
 
T. b. brucei strain Transfected line 
427 VSG - 4, 5, 10, 17 and 20 
GVR35 VSL – 1, 2, 4, 8, 21, 22, 29, 40, 42, and 51 
Table 2.1 T. b. brucei strains produced from transfection with pTb-AMLuc construct 
2.4 Bioluminescence assessment in vitro of transfected strains 
 
Parasites were pelleted at 1000g for 10 minutes, washed once in Phosphate 
buffered saline (PBS) and then lysed in CCLR (cell culture lysis reagent) buffer 
(Promega, UK). The luciferase activity was assessed using the Promega Luciferase 
assay kit (Promega, UK) and the bioluminescence read on the Spectramax plate 
reader (Molecular Devices) at 610 -620nm. 
The transfected lines that produced high bioluminescence and performed well in 
vitro were selected for further investigation in vivo. 
2.5 In vivo validation 
2.5.1 Mice 
 
Female CD1 mice in weight range of 20-25g (Charles River, UK) were housed in 
groups no larger than five in specific pathogen-free individually vented cages, and 
were fed ad libitum. All work was carried out under the approval of the UK Home 
Office Animals (Scientific Procedures) Act 1986, Project Licence PPL 70/6997, and 
the London School of Hygiene & Tropical Medicine AWERB (Animal Welfare and 
Ethics Review Body). ARRIVE guidelines are followed in this report (Kilkenny et 
al., 2010). 
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2.5.2 Infection of passage and experimental mice 
 
A frozen stabilate was thawed and trypanosomes diluted to 2x104 in phosphate 
buffered glucose saline (PBS-G) pH 8.0 as described (Jennings et al., 2002). The 
diluted trypanosomes were injected into donor mice by the intraperitoneal route 
(i.p.). 
Peripheral parasitaemia was monitored via blood films and after approximately 5-
7 days post-infection (p.i), mice were culled via cardiac puncture and blood 
collected. 
 
Experimental mice were infected as per Kennedy et al with minor modifications 
(Kennedy et al., 1997). From a donor mouse (detailed above), 2 x 104 
trypanosomes/mL were diluted in PBS-G as described (Jennings et al., 2002) and 
injected by the intravenous (i.v) route. Mice were then randomised into groups of 
6 (2 cages of 3 mice). 
2.5.3  In vivo bioluminescence imaging  
 
Infected mice (detailed in 2.4.2) were monitored every 7 days via blood 
microscopy and by whole animal imaging (all VSL-2 mice and a control group of 
WT mice). Luciferase substrate D-luciferin was administered i.p at 150 mg/kg 
(Perkin Elmer, UK diluted in Dulbecco’s Phosphate Buffered Saline) and after 10 
minutes (see appendix 1 for luciferin kinetics), imaged using a standard set of 
exposure times in an IVIS® Lumina II (Perkin Elmer, UK) under anaesthesia (2% 
isofluorane/O2 mix at 2.5 L/min). All images were acquired using the following 
exposure times; 1, 3, 10, 30, 60 and 180 seconds, with medium binning, 1 f/stop 
and an open filter, and field of view E (12.5 x 12.5 cm).  
To confirm CNS infection, ex vivo imaging of perfused brains was performed. After 
whole animal imaging, mice were culled via cardiac puncture under terminal 
anaesthesia, and the blood was mixed with a chaotropic salt (6M guanidine HCl- 
2M EDTA) in a 50/50 solution and stored at 4°C for DNA extraction and qPCR (see 
2.6). Mice were then perfused with 20 mL of 1% D-Luciferin in PBS via the heart. 
The brain was then excised and transferred to a Petri dish. Prior to imaging, 50 µL 
of 15 mg/mL luciferin was pipetted onto the brain and imaged using the settings as 
above. All images were analysed using Living Image® software as detailed in 2.5.4. 
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After imaging the brains were snap frozen on dry ice and stored at -80°C for DNA 
extraction and qPCR. 
2.5.4 Quantification of bioluminescence 
 
Bioluminescence was quantified using the region of interest (ROI) with Living 
Image® v.4.2 software (Perkin Elmer) and corrected for background 
bioluminescence. 
The ROI was determined by removing the signal from the image and a rectangular 
ROI (for whole animal quantitation) was positioned on the image to cover (as close 
to, due to varying size) tip of the nose to base of the tail of the mouse. The same 
size box was used for every animal and every time point. When looking at the ROI 
for the brain a circular ROI was used in the same way, positioning it where the 
brain would be (see figure 2.1).  
 
Figure 2.1. ROI calculation for both whole animal (A) and brain (B) 
2.6  Real-time quantitative PCR to determine parasite load. 
 
Real-time quantitative PCR was used to determine parasite load of T. b. brucei 
GVR35 (WT and transfected lines) in cardiac blood and perfused brain material, 
using a primer sequence to target the invariant surface glycoprotein (ISG-75). 
Primer sequence was designed by Dr. Eleanor Barnwell by determining a gene 
present in trypanosomes and not mice (using GeneDB and checking in BLAST, 
Basic Local Alignment Search Tool), and supplied by Sigma Aldrich, UK.  
DNA was extracted from whole brain homogenate and cardiac blood using Roche 
High Pure PCR template kit according to manufacturer’s instruction (Roche UK) 
and quantified by spectrophotometry on a Nanodrop ND1000 instrument (Thermo 
Scientific, UK).  
A B B
A 
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Standards for the gene ISG-75 were generated by conventional PCR from T. b. 
brucei GVR35-derived cDNA, followed by purification using the QIAquick PCR 
purification kit (Qiagen, UK,). Copy numbers were calculated based on the 
fragment length, and standards were used in subsequent assays to generate 
standard curves ranging from 108 copies to 10 copies/reaction. The levels of 
ISG-75 in the indicated samples were measured by real-time quantitative PCR 
using SYBR® Green (Applied Biosystems) incorporation in an ABI Prism 7000 
sequence detection system (Applied Biosystems) relative to the standard curve. 
Each reaction was performed in duplicate with 4 µL DNA, 10 µL SYBR® Green 
master mix, 0.2 µL each primer (final concentration 200 nM), and 5.6 µL water, to 
produce a reaction volume of 20 µL. PCR conditions were 10 min 95°C 
denaturation step, followed by 40 cycles of 95°C: 15 s/60°C: 1 min/72°C: 1 s. 
Primer sequences were: ISG FW: 5’-TTGCTGATAAAGTTGCAGAGGA -3’, and 
ISG RW: 5’ – CAACTCGAACTCTATATAACCAGCA-3’ 
2.7 In vivo drug efficacy and relapse evaluation 
 
Mice (as detailed in 2.5.1) were infected with T. b brucei GVR35 WT and VSL-2 as 
described in 2.5.2. A CNS control group treated with analytical grade diminazene 
aceturate, DA (Sigma-Aldrich, UK) at 40 mg/kg intraperitoneally (i.p), which clears 
peripheral parasitaemia, a drug-treated positive control group of melarsoprol 
treated mice with 15 mg/kg i.p for 3 days and a negative control group of 
untreated infected mice, was included for both strains. Mice were randomised into 
groups of six with a single group per drug/dose. 
Details of drugs and administration is detailed in table 2.2 and drug structures can 
be found in Figure 2.2 
 
 
 
 
 
 
 
 
  
52 
Drug Source 
Dose 
(mg/kg) 
Carrier Route 
Duration 
(days) 
Melarsoprol Sanofi, FR 10, 6, 3, 1 
IV formulation consisting of 10% 
v/v 1, 3-Dimethyl-2-
imidazolidinone (Sigma Aldrich, 
UK), 10% v/v 1-Methyl-2-
pyrrolidinone (Sigma Aldrich, UK), 
35% v/v propylene glycol (Sigma 
Aldrich, UK) and 45% v/v 50 mM 
glycine/HCl (Sigma Aldrich, UK), 
which was then diluted to 10% 
v/v in 5% dextrose solution 
i.v 4 
Fexinidazole Sanofi, FR 
200, 66.7, 
22.2, 7.41 
Oral formulation 0.5% w/v 
Methylcellulose (Sigma, UK) and 
5% v/v Tween 80 (Sigma, UK) 
dissolved in sterile H2O. 
p.o 
(oral) 
5 
DFMO Sanofi, FR 
1000, 
800, 400, 
200 
Dissolved in sterile physiological 
saline (0.9% w/v sodium chloride; 
Sigma, UK) 
i.v 4 
Nifurtimox 
Bayer 
Schering, 
DE 
200 
Oral formulation 0.5% w/v 
Methylcellulose (Sigma, UK) and 
5% v/v Tween 80 (Sigma, UK) 
dissolved in sterile H2O. 
p.o 4 
Diminazene 
aceturate 
Sigma 
Aldrich 
40 Dissolved in sterile dH2O i.p 1 
 
Table 2.2 Drug doses and formulations 
 
Mice were monitored via imaging and blood films (from the tail vein) every 4-5 
days until D35. At D35 mice were culled and qPCR analysis carried out on blood 
and brain samples to determine parasite burden as detailed in 2.6.  
To assess relapse, two doses (10 mg/kg and 6 mg/kg) of melarsoprol were used 
and, following the same protocol described above, mice were infected and dosed. 
Mice were imaged and blood filmed (from the tail vein) every 7 days from D35 to 
D180. Mice were culled when humane endpoints (weight loss >20% total body 
weight, reluctance to move or feed for > 4-6 hrs and/or hind-leg paralysis) of the 
experiment were reached. 
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2.8 Pharmacokinetic studies 
 
To assess the concentration of melarsoprol and the qualitative PK profile of 
fexinidazole present in the brain and plasma, pharmacokinetic studies and analysis 
were carried out in collaboration with Dr. Hatem Sallam and Dr. Andy Harris at 
Pharmidex, UK on samples prepared by the author using LC-MS/MS. 
2.8.1 In vivo  
 
Groups of 3 mice per time point were infected with VSL-2 as detailed in 2.5.2. An 
additional group of 3 mice per time point were used as uninfected controls. At D24 
p.i, a single dose of melarsoprol or fexinidazole (10 mg/kg and 200 mg/kg 
respectively) was administered to both uninfected and infected mice (see table 2.2 
for formulation). At certain time points (see figure 4.7, p 94 and figure 6.6, p 120) 
mice were culled via cardiac puncture (collecting a minimum of 500 μl of blood) 
under terminal anaesthesia, and plasma was collected by centrifugation of 
heparinized blood at 2000 g for 10 minutes. The plasma was then snap frozen on 
dry ice and stored at -80C. Perfused brains (with PBS via the hepatic portal vein) 
were also collected (as detailed in 2.5.3), snap frozen on dry ice and stored at -
80C. 
2.8.2 Drug extractions from brain tissue 
 
Brains were weighed and 0.1% v/v formic acid was added at a weight : volume 
ratio of 1:1 into 1.5ml SuperLock Microcentrifuge tubes (StarLab, UK). Then 4-5 
1.0 mm zirconium oxide beads (Next Advance, UK) were added and the tube was 
placed in a Bullet blender BBY5E (Next Advance, UK) for 5 minutes at speed 8. 
In a clean microcentrifuge tube, 50 l of homogenised brain was added to 150 l of 
extraction buffer (containing internal standard tolbutamide) provided by 
Pharmidex. The tube was vortexed for 1 minute and further centrifuged at 3000 g 
at 4C for 20 minutes. The supernatant was then collected and stored at -20C for 
further analysis by LC-MS/MS at Pharmidex (see 2.8.4). 
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2.8.3  Drug extractions from plasma 
 
For drug extraction 50 l of plasma was added to 150 l of extraction buffer in a 
clean microcentrifuge tube and vortexed for 1 minute. The tube was then 
centrifuged at 3000 g at 4C for 20 minutes. The supernatant was then collected 
and stored at -20C for further analysis by LC-MS/MS at Pharmidex, UK. 
 
For melarsoprol, a standard curve was generated for both plasma and brain 
samples using a serial dilution of melarsoprol. The dilutions were added to 
homogenized brain or plasma of an untreated mouse and extracted as detailed 
above. 
2.8.4  Pharmacokinetic analysis 
 
The drug extractions were analysed using an Agilent 1200 HPLC and auto sampler 
combined with an Agilent 6410A triple quadrupole mass spectrometer (Agilent 
Technologies, UK). All work was carried out at Pharmidex, UK by Dr. Hatem Sallam 
and Dr. Andy Harris. 
2.8.5 Melarsoprol binding assays 
 
The free fraction of melarsoprol in plasma and brain tissue was determined by 
Rapid Equilibrium Dialysis. Using a dual compartment well separated by a dialysis 
membrane, melarsoprol-spiked plasma or brain homogenate was loaded into the 
first compartment (bound) with PBS placed in the other (free). The well was 
sealed and incubated at 37C on an orbital shaker for 4 hours to achieve 
equilibrium between the two compartments. After incubation, the samples 
underwent extraction (as described in 2.8.3) and the concentration of melarsoprol 
was quantified using LC-MS/MS with the results expressed as either % bound or 
free.  
2.9 Data analysis 
 
All data was analysed using Microsoft Excel and GraphPad Prism® v.6.02 for 
statistical analysis (see figures for tests used) 
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Figure 2.2 Drug structure of current anti-trypanosomals. 
Melarsoprol 
Fexinidazole 
Eflornithine, DFMO 
Nifurtimox 
Diminazene aceturate 
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CHAPTER 3: Development of T. brucei bioluminescence imaging model 
3.1 Introduction 
 
Currently, mouse models involved in HAT drug development are used either for 
the early stage of the infection, using the monomorphic line T. b. brucei Lister 427 
(or a derivative), or for the late stage, using the ‘gold standard’ pleiomorphic strain 
T. b. brucei GVR35 (Jennings, 1977).  
 
One of the first T. brucei strains to be maintained within the axenic culture method 
developed by Hirumi was T. b. brucei 427 (Hirumi et al., 1977).  
Lister 427 was first isolated from cattle in Tanganyika in 1956, and was 
transferred to the Lister Institute in London where it was serially passaged 
through mice for 15 passages before being frozen at -70C (Claes et al., 2009).  
The strain T. b. brucei 427 is a well-defined monomorphic line and remains solely 
as the bloodstream form (BSF) of the parasite (Cui et al., 2008).  The parasites have 
the characteristic long and slender form, and produce high parasitaemia both in 
vitro and in vivo. 427 adaptation to in vitro culture has made it an invaluable tool in 
molecular biology (Claes et al., 2009). 
 
The use of T. b. brucei 427 has not been limited to genetic studies; its rapid 
infection rates meant it was quickly adopted into drug discovery programmes.  
 
The development of a colorimetric assay utilising the substrate resazurin, (or its 
commercial counterpart Alamar blue), resulted in the strain being widely used in 
initial drug screens in vitro to determine drug efficacy against BSF (Raz et al., 
1997). The in vitro assay could determine inhibitory concentrations (IC50 and IC90) 
within three days, providing a huge breakthrough in the first stages of drug 
discovery programmes, by ascertaining whether the compound was active against 
the trypanosome. However, the substrate requires an incubation time of 
approximately six hours, which has limited the use of the assay for anything other 
than endpoint studies. Time-kill evaluation of drugs can only currently be carried 
out by manually counting parasites, especially if short time points are being 
determined (under six hours for example). 
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With access to an easily cultured BSF of T. b. brucei, other areas of the infection 
could be investigated further, such as the parasites ability to switch its variable 
surface glycoprotein (VSG) to evade host immune defenses (Claes et al., 2009). The 
strain is also easy to genetically manipulate by the insertion or deletion of certain 
genes. This methodology has been used in the study of RNA interference (RNAi), to 
discover new drug targets and resistance (Kristensson et al., 2013, Jayakumar et 
al., 2013).  
As discussed in chapter one, 427 is also infectious to mammalian hosts (rodents) 
but remains within the first stage of the disease. This has made the strain ideal as a 
model for the study of the acute stage of infection and drug evaluation, especially 
as it is non-infective to humans therefore making it a safer alternative to T. b. 
rhodesiense (Finsterer and Auer, 2013). But T. b. brucei 427’s monomorphic nature 
and inability to invade the CNS is the most limiting factor in terms of mimicking 
the infection of African trypanosomiasis.  
 
The pleiomorphic strain T. b. brucei GVR35 was isolated from a wildebeest in 1966 
in the Serengeti and further developed by Jennings et al in the 1970s to study drug 
therapies of late-stage infection (Jennings, 1977). The line can be easily cultured in 
vitro but grows at a slower rate than Lister 427 requiring a different culture 
technique, as the parasites require passaging more frequently to ensure the 
dividing population remains in culture (slender). Culturing at a lower density also 
prevents the trypanosomes from becoming stressed, therefore transforming to the 
stumpy form (Myburgh et al., 2013). 
 
The development of the reproducible CNS model for trypanosomiasis using GVR35 
in outbred immunocompetent mice, was to primarily produce a model for 
melarsoprol-related PTRE (post-treatment reactive encephalopathy) (Johanson et 
al., 2011). However, the model enhanced the understanding of the late stage, as a 
CNS infection established 21 days post infection (p.i). This development made it 
possible to carry out efficacy testing on late-stage drugs, by following a 180-day 
drug relapse method (Jennings et al., 2002). 
The prolonged amount of time for follow-up was determined as it is known that 
trypanosomes can remain in the CNS for extended periods of time, and due to the 
parasites inaccessibility for quantification (unless the mouse is culled and brain 
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excised), 180-days allows the parasites to relapse in the blood stream if the drug is 
ineffective (Pittella, 2013).  
 
The development of a new model that is able to determine infection without the 
need for parasites to be present in the periphery, or require the culling and qPCR 
analysis on the extracted brain tissue, could greatly reduce the time, cost and 
numbers of animals needed to study CNS infection in late-stage trypanosomiasis.     
 
Bioluminescence imaging (BLI) can provide highly sensitive, non-invasive 
detection of parasite distribution in a mouse model that can be followed in a single 
animal for the entirety of the experiment. An initial bioluminescent model, GVR35-
LUC2 used green light-emitting luciferase (wavelength 520nm) expressed in 
GVR35 was developed to study HAT in a mouse model (Myburgh et al., 2013). But 
with problems of tissue absorption (as detailed in chapter 1) that can occur in the 
green-shifted bioluminescence, it was decided that a red-shifted model will 
provide a more sensitive study tool in the study of trypanosomiasis infection.  
 
An optimized pTb-AMluc-v construct integrated with a humanised red-shifted 
luciferase PpyRE9H that emits light at 617nm (Figure 3.1), was produced by A. 
McLatchie. The incorporation of the luciferase into the ribosomal RNA produced a 
high expression of luciferase. This is due to the ribosomal array within 
trypanosomes containing 10 copies and being well characterised (McLatchie et al., 
2013). The luciferase was surrounded by sequences that modulated the expression 
within the trypanosome, as well as a puromycin selectable drug marker. After 
transfection a clonal population was selected for further analysis (McLatchie et al., 
2013).  
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Figure 3.1 pTb-AMluc construct. (McLatchie et al., 2013) 
 
As discussed in chapter one, one of the major issues with BLI is with the signal not 
being detectable in whole body imaging, as well as the instability of the construct 
within the transfected line.  
The ultimate goal is to study bioluminescence during a CNS infection, it is essential 
that strains have a high intensity signal that can be detected through the skull.  
 
Here, we describe the development of a red-shifted bioluminescence model of 
African trypanosomiasis integrated with the pTb-AMluc-v construct (McLatchie et 
al., 2013). 
3.2  Aims and Objectives 
 
The main aims of this chapter were to develop and validate a red-shifted 
bioluminescence strain of T. b. brucei that is able to produce a signal that can be 
detected in vivo. The two aims were investigated. 
1. Using T. b. brucei 427 as a proof of principle to assess construct stability 
within the trypanosome the following objectives were investigated: 
 Establish a bioluminescence strain that mimics the infection kinetics of a 
wild type strain both in vitro and in vivo. 
 Produce a bioluminescence strain with high intensity signal that can be 
detected in whole animal imaging.  
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 Determine the correlation between traditional blood film parasitaemia and 
bioluminescence. 
 
2. Validation of the pleiomorphic line GVR35 with the following objectives 
were investigated: 
 Establish a bioluminescence strain that mimics the infection kinetics of a 
wild type strain in vitro. 
 Produce a bioluminescence strain with high intensity signal that can be 
detected in whole animal imaging and through the skull of an infected 
mouse. 
 The bioluminescence strain will also have the ability to produce a CNS 
infection that will be visible both in whole animal imaging and ex vivo 
imaging of brain. 
3.3 Contributors 
 
The pTb-AMluc-v construct was designed by Dr. Martin Taylor at the London 
School of Hygiene and Tropical Medicine (LSHTM). The transfections and in vitro 
assessment (growth curves and luciferase activity) were carried out by Alex 
McLatchie. All in vivo experiments were carried out by author including qPCR 
analysis.  
3.4 Results 
3.4.1 Growth and bioluminescence of transfected 427 
 
Using the pTb-AMluc-v construct containing RE9H luciferase reporter genes, a 
number of transfected strains of 427 were produced, using the methodology 
described (McLatchie et al., 2013).  
The bioluminescence of 1 x 106 trypanosomes/ml of each strain was assessed 
using the Promega Luciferase Kit and read on a Molecular Devices Spectramax M3 
(Fig. 3.2) 
Rather than carrying out an endpoint bioluminescence analysis at a single 
wavelength, the samples were analysed over a spectrum of wavelengths from 550 
nm to 750 nm to ensure the transfected red-shifted luciferase was emitting light at 
the correct and optimal wavelength.  
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All of the transfected lines peaked at 610 nm. However, the magnitude of 
bioluminescence emitted differed between the lines.  
VSG5 produced the maximum level of bioluminescence at 610 nm, peaking at 22 
991 relative luminescence units (RLU), significantly (p-value = 0.046) higher than 
VSG17 (the next highest performing strain), which peaked at 10 978.9 RLU.  
 
Based on the bioluminescence analysis the top four transfected lines (VSG4, VSG5, 
VSG10 and VSG17) were chosen, and to ensure the transfection process did not 
alter the infectivity, the growth rate was assessed against the WT (Fig. 3.3). The 
cumulative in vitro growth of VSG-lines were compared to that of the wild type 
daily for 10 days, with a starting parasitaemia of (and diluted down to) 1 x 105 
trypanosomes/ml. Daily haemocytometer counts were recorded and the parasites 
were diluted back to the starting parasitaemia. Figure 3.3 shows that there is no 
significant difference in the growth of the transfected lines to that of the wild type, 
indicating that the infectivity of the strain was not compromised with the addition 
of the pTb-AMluc construct.  
The spectral and growth analysis data provides sufficient evidence that VSG5 is the 
optimum transfected line to be further investigated in vivo. 
3.4.2  Evaluation of bioluminescence in vivo using whole animal imaging. 
 
To confirm that bioluminescence could be detected in vivo and that the strain 
exhibited the same infection kinetics within an animal host, a 4-day infection was 
performed (Fig. 3.4). The experiment was also able to determine whether the use 
of bioluminescence imaging (BLI) can detect trypanosomal infection earlier than 
the traditional blood film method. 
At D1 post infection (p.i), bioluminescence can be seen at the infection site as 
parasites reside within the intraperitoneal cavity. For three days the 
bioluminescence remains focal as seen on D1 but steadily increasing in 
bioluminescence (represented by the yellow and red areas of the heat map scale), 
and disseminated around the infection site. 
At D4 p.i a clear systemic infection can be seen as the signal disseminated 
throughout the mouse, with a peak area of bioluminescence remaining at the 
injection site. 
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The bioluminescence of the entire mouse was quantified using the region of 
interest (ROI) and compared to blood films detecting peripheral parasitaemia (Fig. 
3.5). Despite signal being detected as early as D1 p.i at approximately 107 
photons/seconds (100-fold higher than the background bioluminescence), no 
parasitaemia is observed within the blood films. At D2 parasitaemia is detectable, 
albeit very low, at an average of 10 trypanosomes/10 fields of view (f.o.v). 
With an increase in peripheral parasitaemia, the bioluminescence also increased 
and by D4 p.i the bioluminescence had reached 1010 photons/second, and the 
parasitaemia peaked at approximately 100 trypanosomes/10 fields. At this point 
the mice were culled due to the monomorphic virulent nature of 427, visible in 
mice by weight loss and anaemia.  The parasites continue to divide until the animal 
becomes overwhelmed and eventually dies. 
 
The data also showed how bioluminescence has little variance between animals, 
which is indicated by the narrow error bars seen on the graph. Yet the detection of 
parasites in the blood had a larger margin of error, which may be due to the 
objectiveness of the person counting the slides. 
A direct correlation analysis of bioluminescence vs. parasitaemia of VSG-5, 
ascertained that there was a significant positive correlation between the two 
measurements with an r-value 0.85 and a p-value of <0.0001 (Fig 3.6), indicating 
that for VSG-5 bioluminescence could be used as a quantitative method. 
 
Based on the success of the integration of the construct into T. b. brucei 427 to 
produce a stable bioluminescence line, the construct was transfected into the 
pleiomorphic strain T. b. brucei GVR35. 
 
3.4.3  GVR35 transfected strain validation  
A number of transfected lines were produced and the bioluminescence assessed as 
detailed in 2.4. The in vitro test showed that all the top four transfected lines (Fig. 
3.7) produced a bioluminescence signal that was at least 10-fold higher than the T. 
b. brucei 427-VSG5 strain. The top four producing lines (VSL-1, VSL-2, VSL-8 and 
VSL-21), all produced bioluminescence above 5 x 104 RLUs, with VSL-2 producing 
the maximum bioluminescence in vitro of 2 x 105 RLUs. It is important to note that 
the assessment of bioluminescence of the lines is by lysing the parasites first 
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before a catalyst is added to produce the signal. This results in a high 
bioluminescence signal that is not always indicative of what can be seen in the 
animal model. In order to determine if the bioluminescence could be detected 
through live-animal imaging and if the transfected strain was able to produce a 
CNS infection , the top four producing lines were infected into three CD1 mice via a 
donor as described in Chapter 2.5.2 as a preliminary observation at the 
performance of the strain in vivo.  
 
VSL-8 and VSL-21 
A presentation of animals infected with VSL-8 and VSL-21 over the 35 days 
experiment as detailed by Jennings, can be seen in figure 3.8 (Jennings, 1977). As 
early as D7 p.i, bioluminescence was detected in the lower back of both the VSL-8 
and VSL-21 infected mice. In VSL-8 infected mouse signal was also visible in the 
snout, which may in part be due to the blood being closer to the surface of the skin. 
By D14 signal increased and was distributed throughout the entire body of VSL-21 
infected mouse. The bioluminescence in the VSL-8 mouse appeared not to have 
increased, but became more focal with signal only present in the lower back of the 
mouse. Prior to treatment with diminazene aceturate (DA) the total 
bioluminescent signal (ROI) calculated for the VSL-8 infected mice decreased from 
1.7 x 108 to 6 x 107 photons/second (p/s), due to a disseminated signal (Fig. 3.9). 
Prior to treatment at D21 bioluminescence in the VSL-8 mice had decreased, with 
very low signal around the ears and nose. High bioluminescence of 1.2 x 1010 p/s 
was dispersed through the entire VSL-2 infected mouse at D21 just before 
treatment with DA.  
After DA treatment, bioluminescence dropped and became undetectable in both 
the VSL-8 and VSL-21 mice. At the end of the experiment at D35 the mice were 
imaged before being culled. At this point bioluminescence was still undetectable, 
with the head region also clear of bioluminescence. The brains of the perfused 
mice were imaged, and as with the whole animal imaging, no bioluminescence was 
detected in the excised brains for either of the transfected lines. 
  
VSL-8 had a starting parasitaemia 10 times higher than VSL-21 of 40 
trypanosomes /10 f.o.v. Over the 35-day experiment the peripheral parasitaemia 
decreased, and reduced to zero parasites after DA treatment for both VSL-8 and 
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VSL-21 (Fig 3.9). The bioluminescence for VSL-8 followed a similar pattern as the 
peripheral parasitaemia. Bioluminescence started at approximately 109 
photons/second, but gradually decreased to ~108 at D21 before rapidly falling to 
below background bioluminescence at D35. Despite the low peripheral 
parasitaemia exhibited by VSL-21, there is a stark contrast in the bioluminescence 
produced. During the first 21 days p.i the bioluminescence remained high at 
approximately 1010 photons/second until DA treatment, cleared the signal to 
below background (Fig. 3.9).  
 
Possible explanations for the lack of signal in the brain include: (i) parasites are 
present but the strain had lost the ability to produce bioluminescent signal, 
indicating that the transfected clone was unstable. (ii) the transfected lines had 
lost the capability to invade the CNS, which may be due to the length of time the 
wild-type was in culture prior to transfection, or (iii) that the BBB became 
damaged due to infection and host inflammatory response, resulting in the DA 
passing through and cleared the brain infection. 
The quantitative PCR (qPCR) data (Fig. 3.9) and ex vivo imaging (Fig. 3.8)  
confirmed that there were no trypanosomes present in the brain homogenate, 
indicating that either there was an inability of the clones to enter the CNS, or that 
BBB damage occurred and therefore enabled clearance by DA. 
Due to the lack of CNS infection produced from both VSL-8 and VSL-21, both lines 
were discontinued within this study, and further transfections were carried out. 
 
VSL-1 and VSL-2  
Due to the inability to produce a CNS infection in strains VSL-8 and VSL-21, it was 
decided that the length of time GVR35 remained in culture prior to and post 
transfection, should be kept to a minimum. The strains VSL-1 and VSL-2 produced 
exceptional bioluminescence when tested in vitro (Fig 3.7). 
VSL-1 and VSL-2 were intravenously infected into 3 mice per strain and the 
infection was monitored through blood films and imaging every 7-days, with DA 
treatment carried out on D21 to clear peripheral parasitaemia. At D7 p.i both VSL-
1 and VSL-2 mice had signal in the lower back and snout (Fig. 3.8), VSL-2 had 
additional signal present in axillary/brachial lymph node area. Seven days later 
signal for VSL-1 mice had become visually undetectable on this heat map scale, 
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whereas VSL-2 mice had strong bioluminescence dissipated throughout the entire 
animal, with intense signal (indicated in red of the scale) present in areas with high 
blood flow at the surface, such as the eyes, and ears of the mouse. After treatment 
with DA, bioluminescence in both strains decreased to background (~105 
photons/second) with VSL-1 remaining clear of bioluminescence at D35. The ex 
vivo imaging further confirmed no late stage infection present.  
 
VSL-2 infected mice had a re-emergence of bioluminescence focused in the head 
region of the mouse. The ex vivo imaging of the brain and qPCR confirmed that an 
infection was present and that VSL-2 had successfully infected the CNS. 
The parasitaemia for VSL-1 and VSL-2 over the 35 day experiment followed the 
same pattern but the VSL-1 was approximately 50% lower than VSL-2 (Fig. 3.9). 
Both transfected lines peaked at D14 (VSL-1 40 trypanosomes /10 fields and VSL-2 
85 trypanosomes/ 10 fields) and cleared after DA treatment at D21, and remained 
undetectable at D35 p.i.  
The bioluminescence for VSL-1 was overall low compared to the other transfected 
lines, with a starting bioluminescence at D7 p.i of 1 x 107 photons/second, only 
100-fold higher than the background bioluminescence of 2 x 105 photons/second 
(Fig. 3.10). There was a small amount of fluctuation (drop at D14 before it 
increased again at D21), before the administration of DA caused the 
bioluminescence to decrease to below background level by D35. In contrast, VSL-2 
had a high starting bioluminescence of 1.3 x 108 photons/second (albeit lower 
than VSL-8 and VSL-21), which increased to 5.45 x 109 photons/second at D14 and 
remained high until treatment at D21. DA caused a rapid decrease in 
bioluminescence to 5 x 105 photons/second, just above background before a rise at 
D35 to 2.9 x 106 photons/second. 
 
3.4.4 VSL-2 Validation 
As the VSL-2 transfected line produced bioluminescence in both the early and late-
stage of infection in the GVR35 model, further studies were needed to ensure that 
the model was both reproducible and consistent as a new model for human African 
trypanosomiasis. This involved assessment of VSL-2 growth in vitro compared to 
the wild type, repeating the course of infection experiment with a larger group of 
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animals (six), the correlation of bioluminescence and parasitaemia, and 
determining the detectable bioluminescent limit of the model. 
 
In vitro growth rate  
The cumulative in vitro growth of VSL-2 was compared to that of the wild type (Fig. 
3.10). The parasite growth was monitored daily for 10 days, with a starting 
parasitaemia of (and diluted down to) 1 x 105 trypanosomes/ml. Daily 
haemocytometer counts were recorded and the parasites were diluted back to the 
starting parasitaemia and the cumulative growth calculated 
The growth of VSL-2 was not affected after the transfection of the luciferase. This is 
evident by the growth curve for VSL-2 overlaying that of the wild type. 
 
In vivo bioluminescence assessment 
A repeat of the strain assessment was carried out for VSL-2 with a greater number 
of mice (six).   
A patchy signal was evident throughout the mouse that resided predominantly in 
the lower back region and lymph nodes at D7 p.i (Fig 3.11). The trypanomastigotes 
continued to multiply and spread throughout the blood and lymphatic system, and 
on D14 signal was observed throughout the animal. By D21 a similar signal 
distribution was seen, although the bioluminescence was much higher, peaking at 
1 x 108 photons/second. From the heat-map scale it can be seen that the 
liver/spleen area displays the highest bioluminescence, providing further evidence 
that the lymphatic system is heavily infected.  
Following treatment with DA at D21, bioluminescence in infected animals at D28 
was greatly reduced, with a focal signal found only in the head region, as the 
clearance of peripheral parasitaemia revealed possible CNS infection. By D35, the 
bioluminescence signal in the head region became more intense, as the cranial 
concentration of parasites appeared to increase, with a 10-fold increase in flux 
between D28 and D35.  
Quantification of the images revealed that as the infection progressed, the 
bioluminescence increased from 108 to less than 1010 total flux until DA treatment 
was administered (Fig. 3.12). In comparison parasitaemia was not detectable via 
microscopy until D14 and then was undetectable following treatment with DA. 
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Peripheral parasitaemia remained undetectable until the end of the experiment at 
D35 despite bioluminescence signal clearly apparent in the head. 
To confirm the presence of trypanosomes in brain tissue following whole animal 
imaging at D35, the mice were perfused to clear the tissue of blood, and brains 
were excised and imaged ex vivo (Fig. 3.12). Bioluminescence was detectable in all 
VSL-2-infected mouse brains and was comparable to the signal seen in the head 
region of the respective intact mice at D35 (Fig. 3.11). In the brain of mouse 2, the 
signal was most prominent in the olfactory bulb of the brain whereas in mice 1 and 
3 the signal non-specifically disseminated through the entire brain, with a high 
signal (red ‘hot spot’) in the cerebellum of mouse 3. The remainder of the infected 
group showed similarly non-specific distribution of bioluminescence in the brain 
(not shown). 
Following ex vivo imaging, DNA was extracted from the perfused brains and qPCR 
was used to determine the parasite load in each brain (Fig. 3.12). Comparing qPCR 
to bioluminescence signal, the total flux was representative of the number of 
trypanosomes present. The brain of mouse 3 had areas of higher flux and therefore 
had an overall higher quantity of trypanosomes. Despite showing differences in the 
distribution of parasites, a trend can be identified between parasite burden as 
determined by qPCR and bioluminescence. The control wild type-infected brain 
had no bioluminescence but high parasitaemia. 
 
Correlation of parasitaemia vs. bioluminescence 
To determine if bioluminescence can be used as a quantitative method of 
evaluating parasitaemia, a correlation analysis of peripheral parasitaemia and 
whole animal bioluminescence was carried out (Fig. 3.13). From the analysis of BLI 
and peripheral parasitaemia an r-value of 0.28 was calculated, and suggested that 
the data had a weak positive relationship, as an increase in bioluminescence did 
not necessarily indicate an increase in parasitaemia. This is especially evident as 
the highest amount of bioluminescence can be seen when there is little to no 
parasitaemia.  
 
Limit of Detection 
To ascertain the detectable limit of the model within the Lumina IVIS a 0.2 ml 
serial dilution of parasites (50 – 5 x 104 trypanosomes) was prepared and 20 µl of 
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luciferin added. This was then injected intraperitoneally into CD1 mice and after 
10 minutes mice were imaged (Fig 3.14). At the lowest dilution of 50 
trypanosomes it can be seen that there is no visible bioluminescence present in the 
abdomen of the mice. A small signal is detected in mice infected with 1 x 102 
trypanosomes, and the bioluminescence appeared focused around the site of 
infection. Mice infected with 5 x 102 trypanosomes had a dispersed signal within 
the abdomen, but still produced bioluminescence at the low end of the heat-map 
scale. An increase in trypanosomes had little effect on the dispersal of infection at 
both 1 x 103 and 5 x 103 trypanosomes, as the bioluminescence remained in the 
same area as seen in the lower infections, but with an increase in the intensity of 
the bioluminescence signal. At 1 x 104 trypanosomes, the entirety of the abdomen 
had visible bioluminescence with an area of high intensity around the injection site 
which can be seen with a red ‘hot spot. ’ The top dilution of 5 x 104 trypanosomes  
produced  wide-spread bioluminescence in the intraperitoneal cavity with a large 
area of high intensity and bioluminescence. 
 
3.5 Discussion 
We demonstrate that the integration of the pTb-AMluc-v construct into T. b. brucei, 
is able to produce a bioluminescence strain that is detectable through whole 
animal BLI. 
The transfected line VSG5 was able to exhibit similar virulence properties 
compared to the wild type. 
 
The incorporation of bioluminescence into 427 has produced varying results 
dependent on the type of luciferase that has been used. The strain T. b. brucei 427-
Rluc-pHD309 contains Renilla luciferase, which emits light in the blue spectrum at 
480 nm after the administration of coelentrazine. This emits approximately 106 
RLU for 1 x 106 trypanosomes/ml but is poorly visible within whole animal 
imaging (Claes et al., 2009). Firefly transfected strain (emitting at 562nm), 427-
LUC2 transfected with the TbR-LUC2 construct, produced a bioluminescence 1000 
times lower than the RLUC line  in vitro for the same concentration of 
trypanosomes (~ 103-104 RLU) but had an improved detectability in vivo 
(Myburgh et al., 2013). We have shown that the transfection of a red-shifted 
luciferase into the 427 parasite may not increase the level of bioluminescence in 
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vitro from what has been seen previously (at approximately 2.5 x104 RLUs for 1 x 
106 trypanosomes/ml), but the VSG5 strain had a far better sensitivity in vivo 
compared to both the firefly transfected TbR-LUC2 and the renilla 427-Rluc-
pHD309. Although no parasites can be detected in blood films at D1 p.i a signal is 
indeed present, indicating that low-level infection can be detected through live 
imaging.  
 
The data produced demonstrates that from the initial transfection of T. b. brucei 
GVR35 with pTb-AMluc-v to produce 10 bioluminescent lines. The top four lines 
(VSL-8, VSL-21, VSL-1 and VSL-2) produced a minimum of 3 x 104 RLUs greater 
than the successful 427-VSG5 in vitro.  Despite the impressive results in vitro, only 
VSL-2 was able to produce a bioluminescence signal in the mouse CNS.  
 
An increase in vitro culture time pre and post transfection, affected the infection 
kinetics of the parasite so that it no longer penetrated the CNS (as seen in VSL-8 
and VSL-21 lines). It was decided that parasites would not remain in axenic culture 
for longer than 7 days (to include pre and post transfection), and the second 
generation of transfected lines were produced in this manner (VSL-1 and VSL-2). 
Further validation of VSL-2 indicated that the transfection with the pTb-AMluc-v 
construct did little to alter the infectivity of the parasite. The same growth rate in 
vitro was observed, and it was able to produce both early and late stage infection 
in mice. 
During the 35-day validation, VSL-2 was shown to provide higher imaging 
sensitivity than previous transfected trypanosome strains, with a bioluminescence 
1000-fold higher than the GVR35-LUC2 in vivo (McLatchie et al., 2013, Myburgh et 
al., 2013), with a detectable limit within the IVIS of 100 trypanosomes in a bolus 
infection. 
 
Despite the improved sensitivity and signal that VSL-2 produced, the 
bioluminescence was not directly correlated to the peripheral parasitaemia 
observed in blood films. Literature has documented that the early stage infection 
of trypanosomiasis infects the haemolymphatic system (Brun et al., 2010), and is 
not solely restricted to the blood system. The data produced in this chapter 
supports this, as despite peripheral parasitaemia being undetectable in the blood 
  
70 
films, bioluminescence was visible (and in most cases very high). Even when 
cyclical parasitaemia is observed, bioluminescence remained constant. Further 
experiments to investigate the bioluminescence and parasite burden (determined 
by qPCR) within infected lymph nodes would further support studies by Tanner et 
al, that despite parasite fluctuations in the blood, parasites in the lymph nodes 
remain constant (Kamerkar and Davis, 2012). This however, does mean that 
bioluminescence imaging can only be used as a qualitative measurement of 
infection, and further analysis is required to determine parasite burden. Despite 
this, VSL-2 is an imaging model that could potentially be used in drug development 
studies. The initial detection of infection through imaging and also the loss of 
signal after treatment (and reappearance at relapse) can provide a more sensitive, 
non-invasive drug assessment, with the potential to reduce the time required for 
drug evaluation. 
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Figure 3.2 Spectral analysis of transfected T. b. brucei 427. For each of the transfected strains,  
1 x 106/ml was analysed over the full spectrum and the RLU was determined. 
 
Figure 3.3 Growth curve of transfected T. b. brucei 427. The growth rate of transfected 427 was 
assessed in vitro compared to the WT. At each day the parasitaemia was diluted to 1 x 105/ml and 
the cumulative number of parasites was calculated over a 12-day period.  
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Figure 3.4. In vivo imaging of mice infected with VSG5. Five CD1 mice were infected with VSG5 
via the i.p route. They were monitored by imaging and blood film acquisition for five days post-
infection. Mice imaged at the indicated time points compared to a mouse infected with wild-type 
427, showing bioluminescence on a heat-map scale (total flux) where red is an area of high flux i.e., 
high bioluminescence activity.  
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Figure 3.5 Bioluminescence vs. parasitaemia of VSG5. Quantification of average total flux and 
parasite number from the mice in figure 3.4. Each data point is a mean ± SD of the bioluminescence 
analysis and microscopic counts. 
Figure 3.6 Direct correlation of bioluminescence vs parasitaemia of VSG5. A direct correlation 
analysis determines that it is positively correlated with an r-value of 0.8526. The correlation is also 
significant which is evident with a p-value of <0.0001. Inset shows correlation data expressed with 
a linear scale. 
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Figure 3.7 Spectral analysis of  transfected T. b. brucei GVR35. A 1 x 106 trypanosomes were 
lysed using the Promega Luciferase Activity kit and bioluminescence measured. The red bars 
indicate the strains with the highest in vitro bioluminescence. 
   
Figure 3.8 The in vitro growth rate of three transfected VSL lines. The cumulative growth rate 
of three transfected lines were compared to the WT strain.  
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Figure 3.9 In vivo validation of GVR35 transfected strains. A single representation of three VSL 
infected mice i.v (VSL-1, VSL-2, VSL-8 and VSL-21) imaged at the indicated time points, showing 
bioluminescence on a heat-map scale (total flux) where red is an area of high flux i.e., high 
bioluminescence activity. At D21 mice were treated with DA (b) Excised brains were homogenised 
and extracted DNA subjected to qPCR 
Strain Trypanosomes/ 50ng of DNA 
VSL-8 0 
VSL-21 0 
VSL-1 6354 
VSL-2 9320 
Control 10123 
1 
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Figure 3.10 Bioluminescence and parasite burden of GVR35 transfected lines (a) peripheral 
parasitaemia of six mice. (b) Quantification of average total flux as determined by ROI Each data 
point is a mean ± SD of the bioluminescence analysis and microscopic counts. The red line indicates 
background bioluminescence which was established by imaging a WT-infected mouse. 
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Figure 3.11 Validation of T. b. brucei GVR35 VSL-2  Three representative animals of six VSL-2 
infected mice i.v (M1, M2 and M3) imaged at the indicated time points compared to a mouse 
infected with wild-type GVR35, showing bioluminescence on a heat-map scale (total flux) where 
red is an area of high flux i.e., high bioluminescence activity. At D21 mice were treated with DA. 
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Figure 3.12 Quantification of biolumienscence and parasite burden of VSL-2 (a) 
Quantification of average total flux as determined by ROI, and peripheral parasitaemia of six mice. 
Each data point is a mean ± SD of the bioluminescence analysis and microscopic counts. (b) Excised 
brains were homogenised and extracted DNA subjected to qPCR, and compared to the 
bioluminescence. The detection limit of the qPCR was 50 trypanosomes/50 ng of DNA. 
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Figure 3.13 Direct correlation of bioluminescene vs Parasitaemia. A direct correlation analysis 
determined that the data is not correlated with an r-value of 0.28. This indicates that there is no 
correlation bioluminescence and parasitaemia in VSL-2 strain 
 
 
Figure 3.14 Limit of detection of VSL-2 To determine the detectable limit of the VSL-2 model in 
the IVIS, a bolus of serial diluted trypanosomes and luciferin were infected i.p into an individual 
mouse per dilution and imaged after 7 minutes.  
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CHAPTER 4: Validation of VSL-2 using melarsoprol 
4.1  Introduction 
 
As detailed in chapter 1, melarsoprol was the most widely used late-stage 
treatment due to its affordability and cross-sensitivity to both rhodesiense (the 
only current treatment therapy) and gambiense strains of HAT (Barrett et al., 
2007). 
Melarsoprol is an organoarsenic compound that was developed by adding the 
heavy metal chelator dimercaptopropanol (BAL) to the trivalent arsenical 
melarsen oxide (fig. 5.1). The addition of BAL results in a compound that is 100 
times less toxic than melarsen oxide alone (trypanocidal active component) 
(Barrett, 2004).  
 
Fig. 4.1 Structure and production of melarsoprol (Adapted from www.parasitesandvectors.com) 
 
Melarsoprol was first introduced in 1949 by Ernst A.H. Friedheim and is now 
produced and marketed by Sanofi as Arsobal® (Burri, 2004). Due to poor oral 
bioavailability, melarsoprol treatment regimen consists of intravenous (i.v) 
injections of 2.2 mg/kg /day for 10 days (Burri, 1993).  
 
Despite widespread use, melarsoprol can produce a severe toxic side effect known 
as post-treatment reactive encephalopathic (PTRE) syndrome. Symptoms of which 
can be difficult to distinguish from those of the late-stage infection. They include 
convulsions, fever, headaches, progressive coma and eventually death (Brun et al., 
2010). The frequency of the side effects can vary; approximately 4.7% of 
gambiense patients and approximately 8% of rhodesiense patients experience 
PTRE, with a fatality rate of 44% and 57% respectively (Brun et al., 2010). 
Toxicity is not the only problem with melarsoprol, administration of the drug is 
painful and it is not uncommon for veins to become thrombotic during treatment. 
In recent years, the number of treatment failures has risen to 30%, indicating that 
reduced drug-sensitivity maybe emerging. However, verifying the reduction in 
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drug sensitivity from samples of relapsed cases in the field, is proving problematic 
due to difficulties in culturing the human-infective parasite (Barrett et al., 2007). 
 
As with most anti-trypanosomal drugs, the mechanism of action is not completely 
understood. It is known that when the parasites are exposed to melarsoprol they 
lyse rapidly but ‘how’ is still under debate. It is thought that melarsoprol forms 
stable interactions with the dithiol trypanothione, but whether this interaction 
causes trypanocidal activity is still being explored (Barrett et al., 2007). The 
primary route of uptake of the un-metabolised drug is thought to be through 
passive diffusion (Scott AG, 1997), whereas melarsen oxide is known to enter the 
parasite primarily through the nucleoside transporter P2 (Carter, 1993, Beckers, 
1981), as the removal of this transporter has shown to provide the trypanosome 
with a level of resistance to melarsoprol. However, complete resistance does not 
occur indicating that other secondary routes are also involved (Carter, 1993).  It is 
known that metabolite melarsen oxide is principally responsible for the 
trypanocidal activity of the drug in vivo (Burri, 2004). 
 
Determining the staging of the disease is imperative before starting a treatment 
regime, as all late-stage treatments require hospitalisation. In most cases, 
alternative treatment with the nifurtimox-eflornithine combination therapy 
(NECT) is carried out in gambiense patients, thus avoiding the toxic nature of 
melarsoprol. Alternative dosing routes have been explored but have proven 
unsuccessful due to poor oral bioavailability and the irritant nature of the adjuvant 
(propylene glycol). This results in oral and intramuscular administration being 
impossible (Barrett, 2004).  
 
Presently there are only two registered treatments for late stage HAT, and due to 
the complexities of treatment regimens of NECT (prolonged treatment times and 
the requirement of both oral dosing and i.v infusions), melarsoprol is the only drug 
used as positive control in animal models (Scory et al., 1999). 
 
To further validate the model and determine its usability as a drug assessment 
tool, studies were carried out with melarsoprol to identify if effective dose data 
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could be obtained and determine if relapse is detected earlier using 
bioluminescence imaging. 
4.2 Aims and Objectives  
 
The work described in this chapter, was to use melarsoprol to further validate 
VSL-2. This was to show its suitability in the study of drug evaluation and whether 
current protocols can be carried out in shorter time frames. 
 The following objectives were investigated: 
 Bioluminescence can be used as a qualitative measure of drug efficacy in 
whole animal imaging. 
 The use of qPCR can further confirm dose response seen in vivo and ex vivo 
imaging of late stage infection. 
 The highly sensitive nature of bioluminescence can detect relapse earlier 
than with traditional blood films.  
 Pharmacokinetics studies can determine the concentration of drug able to 
pass through the BBB and determine concentrations of ‘free’ and bound 
drug. 
4.3 Contributors 
 
Within this chapter all in vivo experiments were carried out by author, including 
samples generated for the pharmacokinetic study. Drug extractions of brain and 
blood were also carried out by author, with LC-MS/MS and analysis carried out by 
Dr. Hatem Sallam at Pharmidex. 
4.4 Results 
4.4.1 Drug efficacy  
 
Using bioluminescence to determine dose response, as well as relapse could 
provide enhanced information on a novel compound’s drug efficacy. Mice infected 
with VSL-2 were treated with melarsoprol at doses of 1, 3, 6 and 10mg/kg i.v for 4 
days, as detailed in table 2.2 to provide a dose response. Bioluminescence and 
parasitaemia were measured at D21 (pre-treatment), 24, 28, 30 and 35 (Fig. 4.2).  
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The imaging data shows qualitatively that after treatment all mice have 
undetectable bioluminescence, indicating a clearance of infection that remained 
undetectable until D30. Despite the initial clearance after treatment, mice treated 
with 1 mg/kg had detectable bioluminescence at D30 p.i focused in the head and 
spinal region of the mouse. From its location it can be presumed that the relapsed 
infection is within the CNS of the spine and brain. By D35 the 1 mg/kg treated mice 
had full-body bioluminescence and the 3 mg/kg group exhibited bioluminescence 
within the head region. The region of interest (ROI) quantified the 
bioluminescence throughout the experiment. Immediately after treatment at D24 
p.i both bioluminescence and parasitaemia fell at all doses (Fig. 4.3). As seen in the 
imaging data, the bioluminescence for the 1 mg/kg treated mice continued to 
increase and at D35 was 100-fold greater than background at 108 photons/second. 
Two of the five mice treated with 3 mg/kg dose also had visible signs of relapse at 
D35 located in the head region.  
Peripheral parasitaemia could only be detected in mice treated with 1 mg/kg 
melarsoprol after infection had re-disseminated throughout the entire animal at 
D35, providing further evidence of the improved sensitivity bioluminescence can 
provide (Fig. 4.3). At the higher doses of melarsoprol treatment (6 and 10 mg/kg), 
re-infection was not detectable through both bioluminescence and blood film 
monitoring during the 35 days. 
 
To quantify parasitic burden after treatment at D35, mouse brains were removed 
and qPCR analysis was carried out (Fig. 4.4). With the increasing doses of 
melarsoprol the parasitic burden determined by qPCR decreased, indicating a clear 
dose-dependent effect. The CNS positive control of DA had a high number of 
trypanosomes in the brain (1.5 x 104 trypanosomes/50 ng of DNA), confirming 
that DA was unable to clear parasites in the CNS. The ex vivo imaging of the 
melarsoprol-treated brains correlated with the qPCR data providing evidence that 
bioluminescence can be used to determine a dose dependent effect. 
4.4.2 Drug relapse 
 
To study drug relapse of melarsoprol using the VSL-2 model, a curative dose of 10 
mg/kg and non-curative of 6 mg/kg were administered intravenously. Over a 180-
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day period bioluminescence and parasitaemia for each individual mouse was 
monitored (Fig. 4.5). 
Mice dosed with 6 mg/kg had undetectable parasitaemia prior to D63 in any 
animal (Fig 4.5A), after which low numbers of parasites were detectable in the 
blood of 4 of the 5 animals and an increase of parasitaemia continued until D119. 
However, according to the blood films, mouse 5 remained aparasitaemic during 
the 119 days showing few symptoms other than splenomegaly before being culled. 
Bioluminescence was detected as early as D49 for 3 of the 5 mice, and signal was 
observed in the remaining mice by D63 (Fig. 4.5A). A fluctuation in 
bioluminescence was seen over 56-days prior to the termination of the group (at 
D119) in all mice, however peripheral parasitaemia was not detected. 
 
Parasitaemia was cleared in all mice immediately after treatment of 10 mg/kg 
melarsoprol and four of the five mice remained blood-film negative throughout the 
180 days. At D91 mouse 2 had a peripheral parasitaemia of 14 trypanosomes/10 
fields of view (f.o.v), which decreased at D98 before reappearing again 14 days 
later. The mouse was then culled at D119 after exhibiting lethargy (Fig 4.5A). In 
the 10 mg/kg treated group, drug relapse for mouse 2 was detected 21 days earlier 
using BLI than with the traditional blood film method (detected at D70 rather than 
D91) (Fig. 4.5B). A total flux of 4.64 x 106 photons/seconds (10 fold increase on the 
background) was observed before the bioluminescence fell below background 
detection. It reappeared at D84 and spiked at D119 with 1.27 x 1010 
photons/second, where the mouse reached its humane endpoint and was culled. 
BLI was therefore able to detect drug relapse much earlier than traditional blood 
film. 
4.4.3 Melarsoprol dose ranging 
 
All pharmacokinetic studies were carried out on melarsoprol alone and not the 
metabolites. This was due to melarsen oxide being difficult to fragment and ionize 
in order to set up a LC-MS/MS method of detection (personal communication with 
Dr. Hatem Sallam at Pharmidex). 
The dose ranging experiments were designed to provide an understanding of the 
relationship between dose and exposure within the two-compartments of plasma 
and brain. It is also used to enable modeling of the clinical exposure in humans. 
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Three doses of melarsoprol were chosen: 0.9, 2.2 and 18 mg/kg and they were 
administered intravenously to one uninfected mouse per time point (8 time 
points). 
The concentrations of melarsoprol in plasma were rapidly metabolised and 
removed within 1-2 hours after administration (Fig 4.6). In the brain, only the 
higher doses of melarsoprol (2.2 and 18 mg/kg) were seen to pass through the 
blood-brain barrier at detectable levels. (Fig 4.6) The 18 mg/kg dose was rapidly 
eliminated; mirroring what was seen in plasma but at 100-fold lower 
concentration.  
4.4.4 Melarsoprol binding assays 
 
Using equilibrium assays and LC-MS, the percentage of free and bound fraction of 
melarsoprol was determined in both uninfected brain and plasma.  
  
 Plasma Brain 
Bound 89.1 ± 0.07 91.4 ± 0.3 
Free 10.9 ± 0.07 8.6 ± 0.3 
 
Table 4.1. Percentage of bound and free fractions of melarsoprol in plasma and brain ± the 
standard error of the mean (SEM).  
 
Melarsoprol was predominantly bound to protein in both brain and plasma, with 
approximately the same affinity. The free fraction of melarsoprol in plasma (u, 
plasma) was 10.9% and for brain (u, brain) was  8.6%. 
4.4.5 Pharmacokinetic study of melarsoprol in mouse model 
 
To study the relationship between dose and exposure of melarsoprol within 
infected and uninfected animals, 3 mice per time point (8 time points) were 
treated with a dose of 10 mg/kg and drug extractions from plasma and brain was 
analysed using LC-MS/MS (Fig. 4.7). 
 
The drug concentration in plasma rapidly decreased in the first 5 minutes from 
377 ng/ml to 29 ng/ml in uninfected animals, and 110 ng/ml to 12 ng/ml in VSL-2 
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infected mice. Over the next two hours the plasma concentrations for both the 
infected and uninfected mice fluctuated, but at the two hour time point the infected 
plasma concentrations fell and were below the limit of quantification (LLOQ). 
However, uninfected plasma continued to fluctuate until it dropped to a low of 8 
ng/ml at 4 hours post-dose and further increased to 53 ng/ml (Fig. 4.7A), 
indicating a longer exposure time of melarsoprol in the uninfected mice. The brain 
concentrations of the infected and uninfected mice followed the same pattern by 
decreasing in the first 30 minutes (36 ng/g uninfected and 61 ng/g), but the levels 
of melarsoprol increased at 1 hour post exposure, with both infected and 
uninfected mice having brain concentrations of 243 ng/g and 235 ng/g 
respectively (Fig. 4.7B).    
4.5 Discussion 
 
Chapter 3 showed that VSL-2 was a highly sensitive imaging model that was able to 
detect infection earlier through BLI than with traditional blood films. The model 
was tested with melarsoprol to establish if bioluminescence can be used as a tool 
in determining drug efficacy.   
 
Currently, pre-clinical drug evaluation requires mice to be monitored for up to 180 
days post-infection, with relapse being detected when parasites re-establish an 
infection in the periphery and are detectable via blood films (Kennedy et al., 1997). 
Presently, there is no established in vivo test to determine the dose-dependent 
effect of trypanocidal drugs in the CNS. Here we have shown that by using a 
combination of bioluminescence and qPCR, we are able to detect parasite 
persistence within tissues after drug treatment and provide a visual marker of 
parasite clearance. Parasite quantification by qPCR added to the sensitivity of the 
model, but parameters need to be established to define when successful treatment 
has occurred, i.e. 100% clearance of all parasites. 
 As the model is able to produce detailed data of drug efficacy in real-time through 
in vivo imaging and definitive parasite load through qPCR, the likelihood of 
treatment failures at later experimental studies is limited, but this may also result 
in fewer drugs making it through to the next phase of clinical trials. 
 
  
87 
The current experimental model requires a time period of six months, which is not 
appropriate for drug development, and a new approach is required to speed up the 
process and provide data on time-to-kill and parasite distribution. At present there 
is no current model for assessing a dose dependent effect in CNS in vivo, as it is not 
possible to determine parasite persistence within tissues using contemporary 
techniques.  
Bioluminescent model systems using luciferase have been described for the 
assessment of drugs for other diseases and infections (Barman et al., 2011, Andreu 
et al., 2010, Claes et al., 2009). The development of the green luciferase LUC2 and 
red-shifted VSL-2 strain has paved the way for a new mouse model of HAT that is 
both highly sensitive and non-invasive.  
VSL-2 provides an improved imaging sensitivity than previous transfected 
trypanosome strains, which enables a dose-dependent effect to be detected in 
whole mouse imaging after treatment with melarsoprol.  
The shortened experimental time of 35 days is sufficient to confirm anti-
trypanosomal activity on late-stage HAT by loss of bioluminescence in the brain, 
which has been difficult to determine in vivo before now.  
The increased sensitivity of BLI is demonstrated further in the analysis of drug 
relapse. By D60, a clear indication of sub-curative clearance (in this case 6mg/kg) 
is evident and by 90 days p.i relapse is detected, resulting in the reduction of 
experimental time by 50%. The non-invasive nature of the model also provides an 
option to extend the time required to follow the animals with minimal invasion.  
 
Although 10 mg/kg appeared as a curative dose in 4 of the 5 mice through the 
assessment of peripheral parasitaemia on blood films and bioluminescence, mouse 
2 showed that parasites could persist long after treatment with increasing flux 
around D60, and then again at D81 to D112 suggesting relapse. Early studies 
carried out by Poltera on melarsoprol showed that the regimen of 10 mg/kg x 3 
days i.v, gave no relapse in peripheral parasitaemia detected by blood films, but 
two-thirds of the mice in the study died (Poltera et al., 1981). Poltera concluded 
that melarsoprol was curative as no parasites were found in the peripheral blood 
or brain tissue in all of the mice as determined by histopathological study and 
immunofluorescence (Poltera et al., 1981). Data shown here supports that 
peripheral parasitaemia was not detected, but bioluminescence re-emerged after 
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treatment in one of the five mice through the 180-day experiment, lending further 
evidence to the hypothesis that the lymphatic system is involved in parasite 
latency, and also raises the question on how ‘cure’ can be defined in the mouse 
model. 
The dose ranging studies showed that the rapid decrease of melarsoprol in plasma 
in the first 20 minutes was representative of the distribution of the drug from the 
plasma/blood (central compartment) into the brain (peripheral compartment). 
Over the next 100 minutes the decrease in concentration is gradual as drug 
metabolism and excretion occurred.  
 
By moving into the infected host, the pharmacokinetic studies carried out on 
melarsoprol did not show a difference in drug concentrations in either the plasma 
or brain compartments, of the infected and uninfected mice. This suggests, that the 
infection had not altered the permeability of the BBB, to either let more drug into 
the brain or to prevent it. 
The biggest limitation from the studies was the inability to detect and measure the 
active component of melarsoprol, melarsen oxide. The restriction was due to the 
inability to produce ionisable fragments for LC-MS/MS analysis. 
The pharmacokinetics of melarsoprol as a whole compound does not provide 
accurate information of the drug activity within the animal host. 
 
In summary, we have presented evidence here that the red-shifted bioluminescent 
GVR35 VSL-2 model, has the capability of providing a sensitive drug assessment 
system by non-invasive imaging, with the ability to reduce the current screening 
time by 90 days. In addition to this, the high sensitivity of the imaging combined 
with quantitative methods of qPCR, have allowed a new methodology to be 
developed that can assess drug efficacy of novel drugs for treatment of late stage of 
human African trypanosomiasis.  
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Figure 4.2 Drug efficacy of melarsoprol using bioluminescence imaging. Infected CD1 mice 
were split into groups of six and treated with varying doses of melarsoprol from D21 and 
monitored until D35. A single representative mouse (1 mouse from group of six) from all doses 10 
mg/kg – 1 mg/kg, showing bioluminescence on a heat map scale (red representing maximum flux) 
before and after treatment.   
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Figure 4.3 Bioluminescence and parasitaemia after melarsoprol treatment. The average (of 
six mice) quantification of total flux and parasite number. Each data point is a mean ± SD of the 
bioluminescence analysis and microscopic counts. Red line indicates background bioluminescence 
measured by the BLI of a WT infected mouse 
 
 
 
2 1 2 8 3 5
1 0 5
1 0 6
1 0 7
1 0 8
1 0 9
1 0 1 0
1 0 1 1
T im e  p o s t - in fe c t io n
( D a y s )
B
io
lu
m
in
e
s
c
e
n
c
e
(p
h
o
to
n
s/
se
co
n
d
)
U n tr e a te dD A1 m g / k g
3 m g / k g 6 m g / k g1 0 m g / k g
2 1 2 8 3 5
0
1 0
2 0
3 0
4 0
5 0
6 0
7 0
T im e  p o s t - in fe c t io n
( D a y s )
P
a
r
a
s
it
a
e
m
ia
(p
a
ra
si
te
s 
/
1
0
 f
ie
ld
s)
  
91 
4.4 Ex vivo imaging and parasite burden of excised brain. Brains were removed after perfusion 
and brain homogenates from each of the mice from 4.3 were extracted for DNA and analysed using 
qPCR. Graph shows mean of six mice ± SD of the number of parasites in 50 ng of DNA. The detection 
limit of the qPCR was 50 trypanosomes/50 ng of DNA. 
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4.5 Drug relapse analysis. Early detection of drug relapse of melarsoprol using VSL-2. Mice 
infected with VSL-2 via the intravenous route were imaged and blood filmed at weekly intervals 
post-dose of melarsoprol. Graphs show the bioluminescence and peripheral parasitaemia from a 
group of five mice (M1, M2, M3, M4, and M5) dosed with (a) 6 mg/kg melarsoprol and (b) 10 mg/kg 
melarsoprol. 
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Figure 4.6 Dose ranging studies of melarsoprol. A dose range of melarsoprol was administered 
intravenously and melarsoprol concentrations determined via LC-MS/MS. (A) Shows the 
decreasing concentration of melarsoprol in plasma of the three doses over 120 minute period. (B) 
Shows the decreasing concentration of melarsoprol in brain for 18 mg/kg and 2.2 mg/kg doses 
over 120 minute period. 
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Figure 4.7 Pharmacokinetic study of melarsoprol in VSL-2 infected and uninfected mice. Mice 
dosed with 10 mg/kg were culled at time points 1, 5, 15, 30 minutes, 1, 2, 4 and 6 hours post dose. 
Drug was extracted from plasma and brains and analysed through LC-MS/MS. (A) Concentrations of 
melarsoprol in plasma (central compartment) over 6 hours in infected and uninfected mice. The 
lower limit of quantification (LLOQ) was 10 ng/ml (indicated by dotted red line). (B) Brain 
concentration of melarsoprol in infected and uninfected mice. The LLOQ was 30 ng/g (indicated by 
dotted red line). 
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CHAPTER 5: Bioluminescence as a tool for detection of early drug treatment 
failure with nifurtimox and DFMO 
5.1  Introduction 
 
Since its introduction in 2009, the first line drug for the treatment of gambiense 
late-stage HAT has been the co-administration therapy NECT (nifurtimox and 
eflornithine combination therapy) (Simarro, 2011). Prior to the inclusion of NECT 
onto the WHO Essentials Medicine List there had been no new or improved 
treatment options for HAT for 25 years (Stein et al., 2014).  
 
Nifurtimox is a 5-nitrofuran pro-drug (Fig 5.1), produced by Bayer under the 
brand name Lampit®. As a monotherapy, nifurtimox produced disappointing 
results with 63 % of patients relapsing after treatment with a high frequency of 
adverse reactions (Pepin et al., 1989, Bisser et al., 2007). Because of this, 
nifurtimox currently remains un-registered as a monotherapy treatment of HAT 
(Burri, 2004). 
Fig. 5.1 Structure of Nifurtimox. (Source: http://en.wikipedia.org/wiki/File:Nifurtimox.svg) 
 
The mechanism of action of nifurtimox is still largely unknown. Recently, studies 
have shown that as a prodrug it requires activation by a nitroreductase (NTR) in 
the T. brucei parasite (Hall et al., 2011). Type 1 NTRs are predominantly found 
within bacteria (although in rare cases they have been found in eukaryotes) and 
facilitates the nitroreduction of the nitro groups found in nitroheterocyclic drugs 
(Hall et al., 2011). The presence of type 1 NTR in trypanosomes results in the 
trypanocidal selectivity of nifurtimox, as although mammalian cells have the 
oxygen-sensitive type II NTR, studies by Hall et al have shown that it is the type I 
NTRs that are responsible for the metabolism of nifurtimox (Hall et al., 2011).  
The type I NTR present in the mitochondria of the trypanosome reduces 
nifurtimox to a reactive nitrile derivative, which induces a trypanocidal effect, the 
mechanism of which is still under investigation. (Hall et al., 2011, Croft, 1999).  
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In early studies of nifurtimox monotherapy against melarsoprol-relapsed HAT 
(when melarsoprol treatment had failed), a range of doses and treatment 
durations were attempted, but adverse reactions (including vomiting, insomnia 
and headaches) occurred which appeared to be both dose and duration dependent 
(Bisser et al., 2007). 
 
Prior to the introduction of NECT, DFMO (eflornithine) was the only alternative to 
melarsoprol treatment-failures in gambiense infections. The use of DFMO in the 
treatment of rhodesiense infections is strongly discouraged due to the drugs poor 
efficacy to the strain (Burri, 2004).  
 
DFMO is an analogue of the amino acid ornithine (Fig. 5.2) and is an irreversible 
inhibitor of ornithine decarboxylase (ODC), which is responsible for polyamine 
biosynthesis (Burri, 2004). 
  
 
Fig. 5.2 Structure of α-difluoromethylornithine (DFMO) (Source: 
http://en.wikipedia.org/wiki/Eflornithine) 
  
The mechanism of action of DFMO against trypanosomes is well documented. It is 
understood that the disruption in polyamine synthesis by irreversibly inhibiting 
ODC results in a depletion of polyamines which are essential in the process of 
growth and multiplication within the trypanosomes. The inability of the 
trypanosome to proliferate, in combination with damage caused by the depleting 
polyamines eventually causes the trypanosomes to differentiate to the non-
replicating stumpy form, leaving the parasite open to attack from the host immune 
system. In addition to the disruption in polyamine biosynthesis, changes occur in 
cellular levels within trypanosomes. After DFMO treatment an increase in levels of 
S-adenosyl methionine (hindering the proper methylation of proteins, nucleic 
acids and lipids) and a depletion of trypanothione has been observed, both of 
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which may result in the parasite becoming more susceptible to oxidative stress 
(Yarlett and Bacchi, 1988, Fairlamb et al., 1987). 
 
The ODC enzyme is found in all eukaryotic cells, but within mammalian cells ODC 
has a rapid turnover of between 10-30 minutes. The slow turnover rate of between 
18-19 hours in T. b. gambiense is thought to be why the drug is so effective and 
non-toxic. In comparison, T. b. rhodesiense has a much higher turnover rate (half-
life of 4.3 hours), which is believed to be why DFMO is ineffective against this 
strain (Barrett et al., 2007, Babokhov et al., 2013). 
 
DFMO was introduced as a first-line monotherapy treatment for gambiense HAT in 
1990 after nearly a decade of clinical trials (Milord et al., 1992). Field studies 
carried out by Medécins Sans Frontières (MSF) in 2000 found that despite the drug 
being free-of-charge, few patients were treated with it. This was due to a lack of 
necessary equipment needed for intravenous infusion administration (catheters, 
bags of sterile water, needles etc.) being available. To overcome this issue, WHO 
provided free kits to include all essential items as well as the drug. DFMO 
monotherapy was considerably more expensive, with estimated costs of $350 per 
person for the drug alone (Burri, 2004). 
 
The combination NECT has greatly reduced the length of DFMO treatment 
required. A daily dose of 400mg/kg is still required but can be carried out over two 
i.v infusions and for only 7-days (as opposed to the original 14), combined with 
oral tablets of nifurtimox at 15mg/kg for 10days. This combination has been 
shown to have a cure rate of approximately 98% and the use of a combinational 
therapy greatly reduces the risk of drug resistance occurring (Priotto, 2006).  
 
The cost and ability to transport NECT to remote rural areas makes the treatment 
far from ideal, as the current NECT kit provided by WHO to treat four patients 
(includes all necessary items for DFMO infusion as detailed above, and the drugs) 
weighs approximately 39kg, making it logistically impractical to transport (Eperon 
et al., 2014). 
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Both nifurtimox and DFMO present challenges when used for in vivo studies. The 
use of intravenous infusions within mice is not possible and, as previously 
discussed, nifurtimox has shown poor efficacy against the parasite. In this chapter 
we use bioluminescence to determine whether the activity of either of these two 
poorly efficacious drugs can be detected in the VSL-2 model of late-stage HAT. 
5.2 Aims and objectives 
 
 Bioluminescence imaging (BLI) can demonstrate the dose dependent effect 
of the monotherapy regimes of DFMO and nifurtimox 
 Investigate the limitations of the model by assessing poorly efficacious 
drugs 
5.3 Contributors 
 
All work within this chapter was carried out solely by the author, with consultation 
from Dr. Hatem Sallam regarding dose ranges for eflornithine. 
5.4 Results 
 
We have demonstrated in the previous chapter that BLI can be used to show the 
effect of drugs on parasite burden. Here we assess the trypanocidal activity of 
DFMO and nifurtimox monotherapies within the bioluminescence model. 
5.4.1 DFMO monotherapy against late-stage trypanosomiasis 
 
VSL-2 infected mice were dosed intravenously with DFMO at 200, 400, 800 and 
1000 mg/kg for four days as detailed in Table 2.1. Doses were chosen as the 
maximum tolerable dose for intravenous administration, determined by carrying 
out a dose setting experiment (data not shown). Mice were imaged at D21 (pre-
treatment), D24, D28 and D35 (Fig 5.3).  The imaging data indicated that the 
treatment regime used for DFMO was not effective in reducing parasite burden.  
 
For all doses of DFMO the bioluminescence did not decrease after treatment, with 
a rise in bioluminescence intensity visible from D28 to D35 in all doses, producing 
saturated images. In contrast the DA treated mice had an immediate drop in 
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bioluminescence at D24 which further decreased to produce a focal 
bioluminescence signal in the head region.  
 
The quantification of the bioluminescence (Fig 5.4) parallels the imaging data. All 
groups of mice had approximately the same bioluminescence throughout the 
experiment at 109 to 1010 photons/second. Despite the increase in doses, the 
bioluminescence is equivalent to that of the untreated mice until D35 when the 
treated mice had a bioluminescence of ~ 2 x 1010 photons/second. In contrast the 
untreated mice had a bioluminescence at 6.4 x 109 photons/second. As with the 
qualitative imaging data, the bioluminescence in the DA treated mice dropped after 
treatment from 2.9 x 109 photons/second to just above background at 9.9 x 105 at 
D28. It then proceeded to increase to 4.4 x 106 photons/second as the signal 
appeared in the head region of the mice.  
5.4.2 Nifurtimox monotherapy against late stage trypanosomiasis 
 
Mice infected with VSL-2 were treated with a dose of nifurtimox at 200 mg/kg for 
four days via the oral route. The dose was chosen on the advice of Dr. Hatem 
Sallam to provide a high but tolerable dose that could provide anti-trypanosomal 
activity. (Table 2.1). Mice were imaged at D21 pre-treatment, at D24 (the end of 
treatment) and then at D28 and D35 (Fig 5.5). After treatment the bioluminescence 
did decrease with partial clearance within the whole animal. A reduction in 
bioluminescence in the lower back region was visible, with the highest level of 
bioluminescence being present in the snout of the mouse. By D28, the 
bioluminescence had disseminated throughout the mice with larger areas of signal 
being present around the head and lower back regions. At D35 all mice had 
relapsed with a total dissemination of bioluminescence throughout the animal. The 
control groups of DA (CNS control group) and the melarsoprol (MelB) treated 
group (drug control) had a reduction in bioluminescence after treatment, with 
MelB treated mice remaining clear until the end of the experiment. The DA mice 
had a clear focal bioluminescence signal present in the head from D25 until D35, at 
which point low levels of signal were also present on the back of the mouse. 
 
The ROI data acquired from the images (Fig 5.6) shows that after nifurtimox 
treatment the bioluminescence drops from 6.6 x 109 photons/second to 2.4 x 108 
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photons/second. The bioluminescence then gradually increased over the 11-days, 
returning to the starting bioluminescence prior to treatment of 6.2 x 109 
photons/second.  
5.5 Discussion 
 
In the previous chapter we showed that the dose dependent effect and relapse of a 
drug can be detected through BLI. By assessing the monotherapies of nifurtimox 
and DFMO with BLI we are able to show how the bioluminescence model of VSL-2 
can be used in the study of less efficacious trypanosomal drugs. 
 
The use of DFMO in the treatment of HAT involves a long, complex regimen 
consisting of a continuous 14-day treatment of intravenous infusions of 100 mg/kg 
every six hours (Matovu and Mäser, 2010). This method of treatment is impossible 
to mimic in the animal model due to ethical restrictions. The original studies 
carried out by Bacchi et al administered DFMO to mice in drinking water (after 
being deprived of water for 12 hours). By using this method, mice were 
continuously exposed to the drug therefore enabling constant drug levels to be 
established (Bacchi et al., 1983). However this method of administration makes it 
difficult to determine the exact dose each mouse receives, and in cases of 
treatment failures it is impossible to determine if individual mice received the 
same dose as other animals in the group. Based on this we chose to administer 
DFMO via a single intravenous injection daily to enable controlled administration 
with improved bioavailability (oral bioavailability of DFMO is ~ 50%) (Burri, 
2004). 
 
The limited trypanocidal efficacy of nifurtimox in humans as well as the adverse 
reactions, prevented this drug from being used as a monotherapy treatment 
(Barrett et al., 2007). Pharmacokinetic studies showed that the serum levels of 
nifurtimox after oral administration are low, with a half-life elimination of only 
three hours. The accumulation of nifurtimox across the BBB is also poor at only 
50% of that of serum levels (Burri, 2004). This explains why nifurtimox had a poor 
efficacy within this study. Despite the poor efficacy, BLI was still able to detect the 
low trypanocidal activity. 
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The additive effect of NECT was discovered by Priotto et al, when a number of 
different drug combinations were tested in field clinical trials (Priotto, 2006). 
Many of the dual treatments produced a toxic effect (melarsoprol with DFMO and 
melarsoprol with nifurtimox), but the combination of NECT produced an additive 
effect by reducing adverse reactions, but also produced cure rates equivalent to 
monotherapies (Priotto, 2006).  
 
It was shown that nifurtimox induced oxidative stress in the trypanosome 
(although the exact mechanism is unknown), and DFMO reduced levels of 
trypanothione which has been shown to protect the pathogen against oxidative 
stress. It is this combined effect which leads to the greater therapeutic nature of 
this dual drug treatment (Barrett et al., 2007).  
 
The differences in bioluminescence and therefore parasite burden between NECT 
and the monotherapies, would ideally have been demonstrated in this study 
providing a conclusive data set for NECT treatment. However due to the problems 
of mimicking the DFMO dosing used in NECT treatment, as well as the poor effect 
of  the single i.v administration in the monotherapy experiment, it was decided not 
to carry out a combination study. 
 
The three T. brucei strains; T. b. brucei, T. b. gambiense and T. b. rhodesiense all 
share similar genetic and morphological profiles, which is one of the main reasons 
why T. b. brucei GVR35 is used as a predictive model of the human infection. As 
mentioned in chapter 1 it is important to establish that the use of predictive 
models still have limitations. Although the three strains show similarities, it is 
understood that T. b. brucei is closely related to the zoonotic T. b. rhodesiense. This 
close relationship could explain why DFMO in the GVR35 model is ineffective, as 
this strain may have a more rapid turnover of ODC than the gambiense strain, 
resulting in DFMO being unable to clear parasitaemia. In addition the single i.v 
daily dose, may not have been able to provide sufficient drug concentration levels 
in the plasma and brain to result in a trypanostatic effect. Despite this, GVR35 is 
currently the only model available for late stage HAT within an immunocompetent 
system, but care must be taken when extrapolating data to the human infection. 
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We have shown that despite GVR35 being a successful model of HAT (both in 
terms of gambiense and rhodesiense), there are limitations to its use when 
considering specific drug targets. Whilst it can be argued that GVR35 is not a true 
predictor of gambiense HAT in DFMO studies, the data described in this chapter 
shows that GVR35 mimics the action of DFMO in rhodesiense HAT infection. 
   
With the use of bioluminescence, poor efficacy of both DFMO and nifurtimox was 
identified at early treatment stages. Although a reduction in bioluminescence, and 
therefore parasite burden, could not be detected using DFMO the study was still 
able to show how the bioluminescence model can be used to indicate treatment 
failures; with the ability to show varying degrees of efficacy as seen in the 
nifurtimox treatment group.  
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Figure 5.3. BLI evaluation of DFMO treated mice. Groups of six mice were infected with VSL-2 as 
described in 2.5.2, and at D21 were treated with DFMO at 1 g/kg, 800 mg/kg, 400mg/kg and 
200mg/kg for 5 days i.v. A CNS control group treated with a single dose of DA at 40 mg/kg was 
included Mice were imaged at D21, D25, D28 and D35 post-infection. A single representative of 
groups is represented here against a heat-map scale.  
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Figure 5.4 Bioluminescence after DFMO treatment. The average bioluminescence of the six mice 
per group from figure 5.3 was quantified using Living Image software. All data points are presented 
as mean ± SD. Red line indicates background bioluminescence determined by the BLI of a WT-
infected mouse.   
 
  
105 
Figure 5.5 BLI evaluation of nifurtimox monotherapy Groups of six mice were infected with 
VSL-2 as described in 2.5.2, and at D21 were treated with Nifurtimox at 200 mg/kg for 4 days p.o. A 
CNS control group treated with a single dose of DA at 40 mg/kg and a drug control group of MelB 
treated mice (15 mg/kg for 3 days i.v) was included. Mice were imaged at D21, D25, D28 and D35 
post-infection. A single representative of groups is represented here against a heat-map scale.  
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Figure 5.6 Bioluminescence after nifurtimox treatment. The average bioluminescence of the six 
mice per group from figure 5.5 was quantified using Living Image software. All data points are 
presented as mean ± SD. Red line indicates background bioluminescence determined by the BLI of a 
WT-infected mouse.    
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CHAPTER 6:  Assessment of the dose dependent effect of fexinidazole using 
BLI model 
6.1 Introduction 
 
Fexinidazole looks set on becoming the newest addition to the family of HAT 
treatment therapies, but despite being in phase II/III clinical trials, fexinidazole is 
far from being a “new” drug (Tarral et al., 2014).  
 
The nitroimidazole was re-discovered by the Drugs for Neglected Diseases 
initiative (DNDi) in 2005 through the use of compound mining, i.e. searching public 
and pharmaceutical drug databases for potential candidates (Mogk et al., 2014). 
 
Fexinidazole was first in preclinical development as a broad-spectrum 
antiprotozoal agent in the 1970s and 1980s by Hoeschst AG (now Sanofi-Aventis). 
Its ease of chemical synthesis and the confirmation of in vitro activity against T. 
brucei in 1983 made it an ideal candidate in the treatment of HAT (Torreele et al., 
2010). However, further development of the drug ceased as fexinidazole returned 
positive results in the Ames test (the mutagenic potential of new compounds based 
on a biological assay using bacteria), indicating potential toxicity (Torreele et al., 
2010).  
 
Despite this result DNDi felt that the compound needed further investigation due 
to current therapies (namely melarsoprol) exhibiting serious toxic effects in 
patients and therefore needing to be replaced. Studies carried out with Sanofi and 
the Swiss Tropical and Public Health Institute (Swiss TPH) in collaboration with 
DNDi re-evaluated the efficacy and preclinical profile of fexinidazole and found 
that, despite producing a positive result in the Ames test, it was shown not to be 
mutagenic to mammalian cells (both in vitro and in vivo) (Torreele et al., 2010). 
 
Fexinidazole is a pro-drug and is rapidly metabolized into two active metabolites: 
fexinidazole sulfoxide and fexinidazole sulfone (Fig. 6.1) (Tarral et al., 2014) 
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Figure 6.1 Metabolism of fexinidazole. Fexinidazole (1-methyl-2-((p-(methylthio) phenoxy) 
methyl)-5-nitroimidazole is rapidly metabolized by oxidation by either cytochrome P450 (CYP) or 
flavin-containing monooxygenase (FMO) to produce the active metabolites sulfoxide and sulfone. 
 
The mechanism of action of fexinidazole is currently unknown but research 
indicates that it has a similar action to other 5-nitroimidazoles by causing a 
negative redox potential within the trypanosome during the reduction to the 
sulfone and sulfoxide metabolites (Eperon et al., 2014).  
 
The oral administration of fexinidazole has shown to cure acute (early stage) T. b. 
rhodesiense and T. b. gambiense in in vivo models with a four-day treatment 
regimen of 100 mg/kg/day. More importantly however, a five-day oral treatment 
regimen of 200 mg/kg/day provided cure in 7/8 mice for up to ~162-days before 
relapse occurred, using the late-stage GVR35 mouse model (Torreele et al., 2010). 
 
Current phase II/III clinical trials are being carried out in Africa and are looking at 
fexinidazole treatment in comparison with the combinational therapy NECT in 
terms of safety and efficacy. The 10-day oral treatment regimen currently being 
studied is split in to two parts: the first consists of 1800 mg/day dose (3 x 600 mg 
tablet taken with food) for four days, followed by six days at 1200 mg/day (2 x 
600mg to be taken with food). The trial will also look at dose ranging to determine 
if lower doses and shorter treatment regimens can be used (DNDi, 2014).  
 
Compared to the current treatment therapy of melarsoprol, the doses involved in 
fexinidazole treatment are large. Melarsoprol treatment is currently 2.2 mg/kg x 
10 days i.v, whilst NECT therapy is complex with a combination of nifurtimox 
tablets being administered three times a day (total 15 mg/kg/day) x 10 days in 
addition to twice daily two hour i.v infusions of 200 mg/kg of eflornithine. If 
fexinidazole is successful in clinical trials it will become the first oral drug for early 
and late stage HAT. This would enable effective treatment in rural endemic areas 
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where complex treatments requiring hospitalization are currently limiting the 
curing of the disease (DNDi, 2014). 
  
To further validate the model and determine its usability as a drug assessment 
tool, studies were carried out with fexinidazole to identify if effective dose data 
could be obtained using bioluminescence imaging. 
6.2 Aims and objectives 
 
The main aim of this chapter was to compare the drug sensitivity of VSL-2 to the 
wild type (WT) GVR35 strain and to investigate the relationship between parasite 
and drug distribution using BLI and PK analysis. The following objectives were 
investigated: 
 Bioluminescence can be used as a qualitative measure of drug efficacy in 
whole animal imaging and provide a qualitative example of a time-kill effect 
of the drug. 
 Quantitative PCR can further confirm dose effect seen in vivo and ex vivo 
imaging of late stage infection. 
 Determine that there is no significant difference in the drug sensitivity of 
fexinidazole in WT and VSL-2 infected mice. 
 PK analysis on fexinidazole and active metabolites can provide information 
on the relationship of drug and parasite distribution. 
6.3  Contributors 
 
Within this chapter all in vivo experiments were carried out by the author 
including the preparation of samples for PK analysis. PK analysis was carried out 
by Dr. Andy Harris at Pharmidex, UK.  
6.4  Results 
6.4.1  Drug efficacy 
 
VSL-2 infected mice were treated with a fexinidazole dose range of 7.4, 22.2, 66.7 
and 200 mg/kg with six mice per dose (Table 2.1). The dose of 200mg/kg has been 
shown to be effective in mouse studies carried out by Torreele et al and was 
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therefore chosen to be the curative dose of this study (Torreele et al., 2010). 
Bioluminescence and parasitaemia were assessed prior to treatment at D21 p.i and 
then at D25, 28, 30 and 35 (Fig. 6.2).   
 
The BLI data shows that after treatment (D25) 66.7 mg/kg and 200 mg/kg treated 
mice were the only doses able to clear the infection. At the lower doses of 7.4 
mg/kg and 22.2 mg/kg, bioluminescence was detected immediately after 
treatment at D25. The bioluminescence in 7.4 mg/kg treated mice decreased after 
treatment (indicated as blue areas) but was still above background detection, 
whereas the 22.2 mg/kg treated mice exhibited an almost complete clearance in 
bioluminescence with just the highly vascular areas of the nose and feet having 
detectable signal. Three days later at D28, mice treated with the top doses of 66.7 
and 200 mg/kg were still negative for detectable bioluminescence, indicating a 
clearance in trypanosome infection. Bioluminescence in mice treated with 22.2 
mg/kg did not increase in intensity but dissemination through the mouse was 
present. Relapse of trypanosome infection occurred in the 7.4 mg/kg treated mice 
at D28 with disseminated bioluminescence similar to D21.  
 
At the end of the experiment three of the four doses had relapsed, as shown by 
varying bioluminescence, indicating a dose dependent effect. The 66.7 mg/kg 
treatment group, despite presenting with no detectable bioluminescence seven 
days prior, had early stages of drug relapse with bioluminescence being present 
throughout the entire animal. Mice treated with 200 mg/kg presented with no 
bioluminescence at D35 indicating that the mice were clear of infection.  
 
In order to quantify the dose dependent effect the average bioluminescence of 
each group was determined (Fig 6.3A). The quantification of the bioluminescence 
provided further evidence that BLI can provide dose effect data. All four doses 
showed an initial drop in bioluminescence from ~1010 photons/second (p/s) to 2.8 
x 109 p/s (7.4 mg/kg group), 8.5 x 107 p/s (22.2 mg/kg group) and to just above 
background at 1 x 106 for 66.7 mg/kg and 200mg/kg treated mice. 
Bioluminescence in the three relapsed doses (7.4, 22 and 66.7 mg/kg) increased as 
the infection reappeared from D28.  
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A rapid drop in bioluminescence from 1010 photons/second to below background 
detection of 6 x 105 photons/second was seen in the 200 mg/kg treated group, 
where it remained until the end of the experiment. The blood films (Fig 6.3B) also 
detected the initial drop in parasitaemia after treatment, with all treated groups 
except the low dose of 7.4 mg/kg (parasitaemia of 9 trypanosomes/ 10 f.o.v), 
exhibiting undetectable parasitaemia.  
At D28, the 7.4 mg/kg treated group had a slight increase in parasitaemia to 28 
trypanosomes/ 10-f.ov. Mice treated with 200 mg/kg of fexinidazole and DA 
remained blood-film negative until the end of the experiment.  
 
At the end of the 35-day experiment both the VSL-2 and WT mice were culled and 
the perfused brains removed for qPCR analysis to determine parasite burden (2.10 
for details). The excised brains of the VSL-2 mice were also imaged prior to 
freezing (Fig. 6.4). The BLI and qPCR data of the excised brains reflected what was 
seen in whole animal imaging: that the increasing doses of fexinidazole produced 
lower bioluminescence and a decrease in parasitic burden. As seen in chapter 4 in 
the study of melarsoprol, the BLI and qPCR data shows a strong correlation, 
indicating that bioluminescence can be used as a viable tool in CNS drug efficacy 
studies. 
6.4.2 Comparison of VSL-2 and GVR35 WT 
 
To determine if the VSL-2 model reacted with the same drug sensitivity as the 
established GVR35 WT strain a comparative study was carried out. Mice were split 
into two groups and infected with either the VSL-2 or the WT strain as detailed in 
2.4.2. The mice were further sub-grouped and treated with four varying doses of 
fexinidazole (7.4, 22.2, 66.7 ad 200 mg/kg), six mice per dose per strain. At D35 p.i 
mice were culled and the parasite burden within the brain was determined by 
qPCR (Fig. 6.5).  
 
At each dose there was no significant difference between VSL-2 and WT response 
to fexinidazole. At 66.7 mg/kg the difference between the two strains was greater 
with the VSL-2 strain having a burden of 439 trypanosomes/50ng of DNA whilst 
the WT had just over four times less parasites with a burden of 105 
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trypanosomes/ 50ng of DNA. The DA and untreated data for the VSL-2 and WT 
strains was impressive, with VSL-2 having a similar parasite burden to the WT. 
6.4.3 Pharmacokinetic analysis of fexinidazole and metabolites. 
 
A preliminary qualitative pharmacokinetic study to look at the relationship 
between dose and exposure of fexinidazole and metabolites was carried out within 
infected and uninfected animals. 3 mice per time point (8 time points) were 
treated with a dose of 200 mg/kg, and drug extractions from plasma and brain was 
analysed using LC-MS/MS. The data is presented as the mean peak area of the LC-
MS/MS trace (Fig. 6.6). 
 
The time-dependent plasma PK profile of infected mice, show that after 
fexinidazole administration there was an initial decrease as the drug was absorbed 
and distributed throughout the body. At one hour post-administration, 
approximately a 20-fold increase in fexinidazole occurred, before drug levels 
stabilized and decreased over the 21-hour period as the drug was metabolised. 
The fexinidazole plasma levels in the uninfected mice had a shorter peak (at 2 
hours post dose) and a more rapid decrease and elimination of the drug occurred 
over the 21-hours. As the parent compound was metabolised, levels of both 
sulfoxide and sulfone gradually increased, with sulfone remaining at a constant 
concentration for 8 hours (providing a longer drug exposure) before being 
gradually metabolised.  
 
The time-dependent profile within the brain showed that unlike the levels of 
fexinidazole in plasma, the drug level is 2-fold higher in the uninfected brain than 
the infected brain. At the beginning of sampling (T0) both the uninfected and 
infected brains have low levels of drug (< 10000) before a 6-fold and 2-fold 
increase for the uninfected and infected brains respectively. The drug is then 
rapidly eliminated with the infected brain retaining a longer exposure at 2-4 hours 
than the uninfected brain. The profiles of both of the metabolites within the brain 
mimicked the plasma profile but approximately 10-fold lower.   
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 6.5 Discussion 
 
Earlier chapters within this study have shown the sensitivity of the VSL-2 model 
and its ability to detect early drug relapse and cure. Presently there is no reliable 
method to determine dose dependent effect in real-time late stage HAT. In support 
of the data found in chapter 4 we show that a clear dose effect can be determined 
through both BLI and qPCR.  
 
When determining the pharmacodynamics-pharmacokinetic (PK/PD) parameters 
of a new anti-protozoal, studies predominantly look at the static approach of an 
MIC (minimum inhibitory concentration, the lowest concentration required to 
inhibit growth) which is often determined with an endpoint in vitro assay (Mueller 
et al., 2004).  
 
Pro-drugs tend to perform poorly in in vitro assays as the process of metabolism 
into the active metabolites is hindered in vitro. Studies on the in vitro efficacy of 
fexinidazole, for example, indicated a moderate activity of 0.1 – 0.8 g/ml against 
T. b. gambiense and T. b. rhodesiense. However in vivo studies against the acute and 
chronic stages found that doses of 100 and 200 mg/kg/day produced cure 
(Torreele et al., 2010), which mirrors what this study found in the dose dependent 
studies with the VSL-2 line. 
 
By determining parasite clearance in vivo the active metabolites are taken into 
consideration providing a better understanding of the drug effect in infected 
patients.  
 
The use of static PK/PD models to evaluate preclinical drug profiles has not 
accounted for drug-parasite interactions or how well the drug distributes through 
both the plasma and tissue (Nielsen et al., 2007). By using a dynamic model that 
looks at the relationship between drug distributions within the plasma and tissue 
and the rate-of-kill of a drug (concentration and/or time dependent), an 
understanding of drug-exposure can be established (Mueller et al., 2004). By using 
the bioluminescence model to detect the dose dependent effect of fexinidazole the 
time-kill properties of the drug during a real-time infection can be assessed, as the 
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non-invasive nature of BLI allows infected mice to be imaged a number of times 
post dose. 
 
The preliminary PK profiles of fexinidazole and the metabolites in both the plasma 
and brain showed that fexinidazole and metabolites were able to pass through the 
blood brain barrier at levels similar to that of the plasma. It also showed that as the 
fexinidazole was metabolised, the levels of both sulfoxide and sulfone increased, 
with sulfone having a longer exposure time than sulfoxide, supporting previous 
studies by Tarral and Torreele that sulfone is the more active of the metabolites 
(Tarral et al., 2014, Torreele et al., 2010). The profiles also showed that the slow 
elimination of the 200 mg/kg dose of fexinidazole would result in the parasite 
being exposed to the drug for up to 24 hours, meaning that daily dosing regimens 
are possible. Whilst exact concentrations of the drugs cannot be determined from 
this study, further experiments are currently underway. Studies are also in 
progress to determine the concentrations of fexinidazole and metabolites in 
regions of the brain using microdialysis. This data as well as the quantitative PK 
analysis can provide information on how much drug is present in the brain and 
how well it is distributed. The microdialysis data of drug distribution in the brain 
can then be compared to parasite distribution in the brain by using BLI of brain 
slices. Providing a better understanding of the relationship between drug 
exposure, parasite distribution and rate of kill. 
 
Fexinidazole has also shown promising results in other kinetoplastid diseases, 
with its efficacy being assessed against Chagas and leishmaniasis. Studies carried 
out on Chagas disease found that the active metabolites of sulfoxide and sulfone 
were more effective in treating an acute in vivo mouse model of T. cruzi than the 
parent drug (Bahia et al., 2014). In visceral leishmaniasis both fexinidazole and its 
metabolites were shown to be orally effective with a good distribution and 
absorption of the drug in the target organs of the liver and spleen (Wyllie et al., 
2012). Both preliminary studies indicate that fexinidazole could be a potentially 
useful new oral treatment for the kinetoplastid diseases. 
 
This chapter also addresses the issue of whether the transfection of luciferase in 
the parasite affected its drug sensitivity. This is especially important in drug 
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models where the death of the transfected pathogen may cause an up-regulation of 
cellular markers. If the luciferase is located within an up-regulated marker, an 
overexpression of luciferase may occur and thereby produce a false positive (high 
bioluminescence despite the pathogen dying).  
 
We have shown here that under drug pressure the VSL-2 strain reacts to the same 
drug sensitivity as the WT, with no significant difference at any of the doses. This 
provides evidence that VSL-2 can be used to replace the current drug evaluation 
model T. b. brucei GVR35. 
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Figure 6.2 Dose effect determined by bioluminescence. Determining fexinidazole drug efficacy 
using bioluminescence and qPCR. Infected CD1 mice were split into groups of six and treated with 
varying doses of fexinidazole from D21 and monitored until D35. (a) A single representative mouse 
(1 mouse from group of six) from each dose, showing bioluminescence on a heat map scale (red 
representing maximum flux) before and after treatment. 
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Figure 6.3 Quantification of bioluminescence and parasitaemia The average (of six mice) 
quantification of total flux and parasite number. (A) Each data point is a mean ± SD of the 
bioluminescence analysis as determined by the ROI of the whole animal as detailed in 2.5.4. Red 
line indicates background bioluminescence determined by the BLI of a WT-infected mouse.  (B) The 
average microscopic counts from Giemsa-stained blood films, each data point is a mean ± SD.  
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Figure 6.4 Ex vivo imaging of perfused brain and related qPCR Parasite burden determined by 
brain homogenates from each of the mice from 6.2 were extracted for DNA and analysed using 
qPCR. Graph shows mean of six mice ± SD of the number of parasites in 50 ng of DNA. Ex vivo 
images were obtained by adding 50 μl of luciferin to perfused brains and imaging using the IVIS 
Lumina. The detection limit of the qPCR was 50 trypanosomes/50 ng of DNA. 
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Figure 6.5 Drug sensitivity of VSL-2 vs WT after fexinidazole treatment The parasite burden 
was determined using qPCR and calculated as the number for trypanosomes/ 50 ng of DNA (as 
quantified by Nanodrop of extraction). A two-way ANOVA analysis to determine if the difference 
between the two strains and at each dose was significant. Between each data set it was found to not 
be significant with a p-value > 0.05. 
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Figure 6.6 The pharmacokinetic profile of fexinidazole and metabolites.  A qualitative study on 
the time-dependent PK profile of fexinidazole, sulfoxide and sulfone. Sampling was carried out at the 
following time points post-dose; 15, 30 minutes, 1, 2, 4, 8, 18 and 24 hours. Data is presented as the 
mean peak area (of LC-MS/MS trace) ± SD over time. (A) Fexinidazole in plasma and brain, (B) 
Sulfone in plasma and brain, (C) Sulfoxide. 
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CHAPTER 7: Discussion 
 
At present, the in vivo drug evaluation tools for HAT require lengthy 180-day 
relapse experiments, with no definitive data on the parasite burden within the CNS 
until animals are culled (Kennedy et al., 1997). The in vitro drug assay using 
resazurin is also restrictive, as it requires long incubation times, thus preventing 
time-kill data from  being easily determined (Raz et al., 1997). The development of 
an imaging model utilizing bioluminescent T. b. brucei enables the real-time 
assessment of both infection kinetics and drug activity in in vitro and in vivo 
studies. In this study we have developed and validated a red-shifted 
bioluminescent strain of both the monomorphic T. b. brucei Lister 427 and 
pleiomorphic T. b. brucei GVR35 to aid drug discovery and development.  
 
When evaluating new compounds for potential anti-trypanosomal activity, the 
initial in vitro assessment is carried out using the 72 hour Alamar blue®/ resazurin 
assay. The REDOX indicator of resazurin detects parasite proliferation and is 
ultimately used as an end-point assay. Although resazurin is non-toxic, the long 
incubation time of 4-6 hours of the fluorometric dye means that the ability to 
assess the rate of kill of a drug is impossible, as early time points after drug 
exposure are not detectable.  
 
T. b. brucei 427-VSG5 was originally generated to determine the optimal 
bioluminescent reporter for future studies in the pleiomorphic line. But its 
creation has provided advancement in time-kill and efficacy assays. VSG5 has 
shown the same growth patterns as the WT line both in vitro and in vivo, 
suggesting that the incorporation of the construct has not had a negative effect on 
the trypanosome (McLatchie et al., 2013).  
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The two published bioluminescent 427 strains 427-Rluc-pHD309 (renilla 
luciferase) and 427-LUC2 (green firefly luciferase) show strong bioluminescence 
activity in vitro but fail to produce high bioluminescence when being transferred 
into animal models. Despite the VSG5 line demonstrating similar in vitro results, 
the activity demonstrated in vivo was far greater. This would enable the strain to 
be used in time-kill studies in vivo to determine time-concentration dependent 
data in the acute infection.  
 
A number of lines were produced by transfection of the pleiomorphic strain GVR35 
with varying degrees of success. Initially the four strains VSL-1, 2, 8 and 21 had a 
high level of bioluminescence intensity in vitro, but the move into animals 
produced different results.  With the exception of VSL-2, all lines failed to produce 
a detectable signal in the CNS, with VSL-8 and 21 demonstrating altered infection 
kinetics which resulted in a failure to produce a late-stage infection. High 
bioluminescence intensity of VSL-2 both in vitro and in vivo was due to the 
luciferase being under the control of a strong promoter within the parasite, which 
enabled a high level of expression of the luciferase (McLatchie et al., 2013).  In 
addition to the strong promoter, the red-shifted firefly luciferase (PpyRE9) had 
been further modified to match a human codon bias, which is similar to that of T. b. 
brucei. This resulted in an improved integration and stability of the luciferase 
reporter within the parasite (McLatchie et al., 2013).  
The VSL-2 line provided a higher imaging sensitivity (as few as 100 trypanosomes 
can be detected) than the previous pleiomorphic trypanosome strains AnTaR1-
RLuc (renilla luciferase), GVR35-LUC2 (firefly luciferase), AnTaR1-CBR (click 
beetle luciferase) and AnTaR1-P9 (red-shifted FLuc) (Myburgh et al., 2013, 
McLatchie et al., 2013, Van Reet et al., 2014).  
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The panel of AnTaR1 bioluminescent lines produced by Van Reet et al showed the 
difference between various luciferase reporters, with the RLuc transfected lines 
having the weakest signal in vivo of approximately 107 average radiance 
(photons/s/sr/cm2), and whilst the red-shifted line was transfected with the same 
PpyRE9 luciferase as VSL-2, it produced a 10-fold lower bioluminescent signal 
(Van Reet et al., 2014). 
 
At present there is no model for assessing dose dependent drug efficacy, as 
contemporary techniques (blood films) are unable to determine the level of 
parasite persistence within tissues. The experimental time of the pre-clinical drug 
evaluation model of six months is a hindrance in developing new drug treatments, 
and a new innovative approach is needed.  
The combination of BLI and the VSL-2 model can be used in a shortened 
experimental time of 35 days to confirm drug activity on late-stage HAT by loss of 
bioluminescence in the brain, and qPCR analysis on the excised brains 
subsequently confirms parasite burden.  
 
The high-sensitivity and non-invasive nature of the VSL-2 model was able to assess 
for the first time the dose-dependent effect of the current anti-trypanocidal drug 
treatment; melarsoprol, DFMO, nifurtimox and fexinidazole.  
Using melarsoprol and fexinidazole, the VSL-2 model was able to demonstrate 
positive clearance of infection, relapse and drug failure. Importantly, the VSL-2 
model was able to detect drug relapse 21 days earlier than the conventional 
method of blood films used in the current pre-clinical model (Kennedy et al., 
1997).  
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A quicker assessment of drugs is not the only requirement for a new model, the 
ability to assess drug activity in real-time to understand time-kill activity will help 
pharmacokinetic studies. We have carried out preliminary pharmacokinetic 
studies on a limited number of uninfected mice with nifurtimox, and found that the 
drug was rapidly metabolised within brain homogenate. Further investigations 
will be carried out to determine the metabolites and carry out the study on a larger 
group of infected and uninfected mice. 
Here we have demonstrated that a dose-dependent effect can be established in 35 
days p.i. By 60 days p.i, a sub curative effect can be detected with relapse 
observable by 90 days p.i. These findings reduce the experimental time of the 
current models by 50%. Due to the non-invasive nature of BLI, the monitoring of 
infection can be extended further if required. 
 
In order to replace the current T. b. brucei GVR35 wild type model, the new VSL-2 
line needed to mimic the WT infection kinetics, growth and drug sensitivities. 
Whilst there is evidence to indicate that the transfection of microorganisms can 
alter their ability to maintain growth rates and infections relative to that of the WT 
(Andreu et al., 2011), the transfection of pTbAMLuc-v into T. b. brucei resulted in 
growth rates, infection kinetics and drug sensitivity mirroring that of the wild type, 
as indicated in the drug sensitivity study carried out with fexinidazole and in vitro 
growth curves.  
 
There are limitations in the use of animal models for human infections, and it is 
important to address these issues before data is extrapolated to human level. Many 
of the mouse models commonly used for HAT studies (including the one presented 
here) use the animal parasite T. b. brucei, which is non-infectious to humans 
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(making it a safer alternative within the laboratory), and may not provide a true 
representation of the human infection (Kennedy, 2007).  
Although models have been established using the human-infective forms T. b. 
rhodesiense and T. b. gambiense within mice, they are harder to use due to the 
higher level of containment and health risks associated with them. Rhodesiense 
lines produce an acute infection in immunocompetent mice with a survival of 
approximately 6 days p.i similar to the T. b. brucei 427 strain (but with a higher 
risk of human infection) (Baltz et al., 1985). Gambiense infection in mice is 
complex, with low virulence in immunocompetent mice and parasitaemia taking 
months to appear in the periphery (Beckers, 1981). Whilst the use of 
immunosuppression (through the use of either SCID or immunosuppressant drugs 
such as cyclophosphamide) produces a quicker infection with higher parasitaemia, 
studies using minocycline (drug that reduces the number of immune cells invading 
the CNS) carried out by Masocha et al have shown that a strong immune response 
is involved with the invasion of trypanosomes into the brain, providing 
complications in the use of SCID mice in the study of late stage infection (Brun, 
1999, Masocha et al., 2004). 
 
Despite these issues, the use of mouse models (and predominantly T. b. brucei 
models) has been essential in identifying potential therapeutic targets as well as 
assessing new drug compounds in pre-clinical trials, and until viable alternatives 
have been established, advancements and improvements on the usability of these 
models are imperative in the understanding of infectious diseases. 
 
VSL-2 has provided evidence to support that trypanosomes are present in the 
brain during a late-stage infection. Previous data of direct detection of 
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trypanosomes in the brain has been sparse, as histopathological studies have 
shown the characteristic immune response to the disease rather than actual 
parasites in brain parenchyma (Rodgers, 2010). The high sensitivity of the model 
is also able to provide early detection of drug relapse and efficacy compared to the 
wild type, but its uses can extend beyond drug development, 
 
It is known that trypanosomiasis is a haemolymphatic disease with parasites 
residing in both the blood and lymphatic systems, and the aspiration of the cervical 
lymph node can be used as a diagnostic method, providing parasitological 
confirmation of infection (Brun et al., 2010). The VSL-2 model showed that the 
peripheral parasitaemia could not be correlated with bioluminescence during 
infection. One explanation for this is that the bioluminescence was able to detect 
parasites present within tissues and the lymphatic system. To confirm this, a study 
on the infection kinetics of trypanosomiasis through the early to late stage of 
infection over 35 days could provide further information on where the 
trypanosomes reside. A similar study by Lewis et al on the infection kinetics of a 
bioluminescent T. cruzi strain showed surprising results of the parasite location. 
By tracking the parasite distribution using BLI during a chronic infection, and 
subsequently carrying out ex vivo, histopathology and qPCR analysis, the authors 
found that the T. cruzi parasite resided in the gastrointestinal tract to allow long-
term parasite persistence (Lewis et al., 2014a). By using the method of BLI 
combined with ex vivo imaging, histopathology and qPCR described by Lewis et al 
with the VSL-2 model, we could gain an understanding of where the parasites 
reside during an infection and their movements within the CNS infection. 
At present we are still unsure of where trypanosomes migrate to from the brain, 
but by using BLI we can track even low levels of infection ex vivo. This study could 
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be taken further by assessing parasite load in regions of the brain. This can be 
done by imaging thick slices of VSL-2 infected brain tissue, and areas of 
bioluminescence can be subsequently dissected for qPCR analysis or 
histopathological evaluation, thus reducing the current ‘needle in a haystack’ 
approach of finding trypanosomes in tissue sections.  
 
The ability to detect trypanosomes within tissue sections has been difficult, but 
could be improved by using dual-reporter lines. Although bioluminescence is 
advantageous in in vitro assays and in vivo imaging of whole animals and organs, 
its use in histology is limited. The requirement of a catalytic reaction of the 
bioluminescent substrate means that the parasites need to be metabolically active 
(therefore alive) to produce a light signal, this is not possible when preparing 
sections for microscopic visualisation. By adding a fluorescent protein into the 
construct the parasite can be imaged both macroscopically and microscopically. 
The bioluminescent reporter can be detected in whole animal imaging, and the 
fluorescence detected in microscopy or flow cytometry.  
The combination of a dual reporter line with fluorescent immunostaining of host 
cells could provide evidence of the interactions of the trypanosomes with immune 
cells at the BBB and therefore determine mechanisms of parasite invasion. 
   
In conclusion, in this study we have developed and validated a red-shifted 
bioluminescence model of T. b. brucei, which provides a sensitive drug assessment 
system through non-invasive BLI, which reduces the current screening time by 120 
days.  By combining the high sensitivity of the VSL-2 model with quantitative 
methods of qPCR, we have developed a new methodology that can assess the dose 
dependent effect of novel drugs for the treatment of late stage human African 
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trypanosomiasis, as well as assessing the rate of kill of a drug in a real-time 
infection. The reduction in drug evaluation time that can now be applied to pre-
clinical drug testing will speed up drug development and aid the ongoing progress 
to HAT elimination. 
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Luciferin. Three VSL-2 infected CD1 mice were injected with 150 mg/kg i.p of luciferin and placed 
immediately within the IVIS Lumina. The mice were imaged over 60 minutes and their 
bioluminescence was calculated to determine the optimum imaging window after luciferin 
administration  
 
